Zomedica (ZOM) 10-K 15 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Mar. 15, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-38298
Entity Registrant Name	ZOMEDICA CORP.
Entity Incorporation State Country Code	Z4
Entity Tax Identification Number	00-0000000
Entity Address Address Line 1	100 Phoenix Drive
Entity Address Address Line 2	Suite 125
Entity Address City Or Town	Ann Arbor
Entity Address State Or Province	MI
Entity Address Postal Zip Code	48108
City Area Code	734
Local Phone Number	369-2555
Security 12b Title	Common Shares
Trading Symbol	ZOM
Security Exchange Name	NYSE
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock Shares Outstanding		979,949,668
Entity Public Float			$ 212.6
ICFR Auditor Attestation Flag	false
Auditor Firm ID	248
Auditor Name	GRANT THORNTON LLP
Auditor Location	Cincinnati, Ohio
Entity Central Index Key	0001684144
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 27,399	$ 194,952
Available-for-sale securities	87,693
Trade receivables, net	596	315
Inventory, net	2,746	2,848
Prepaid expenses and deposits	3,799	1,842
Other receivables	1,268	450
Total current assets	123,501	200,407
Prepaid expenses and deposits	188	394
Property and equipment, net	6,809	1,130
Construction in progress	692	420
Right-of-use asset	1,665	1,320
Goodwill	63,979	43,288
Intangible assets, net	41,799	33,176
Non current available-for-sale securities	40,712
Other assets	265	265
Total assets	279,610	280,400
Current liabilities
Accounts payable and accrued liabilities	6,698	3,225
Accrued income taxes	187	240
Current portion of lease obligations	641	415
Customer contract liabilities	207	198
Other current liabilities	78	262
Total current liabilities	7,811	4,340
Lease obligations	1,097	964
Deferred tax liabilities	1,245	3,709
Customer contract liabilities	182	140
Other liabilities	1,883	359
Total liabilities	12,218	9,512
Commitments and contingencies (Note 17)
Shareholders' equity
Unlimited common shares, no par value; 979,949,668 and 979,899,668 issued and outstanding at December 31, 2022 and December 31, 2021	380,973	380,962
Additional paid-in capital	23,666	9,313
Accumulated deficit	(136,404)	(119,389)
Accumulated comprehensive income (loss)	(843)	2
Total shareholders' equity	267,392	270,888
Total liabilities and shareholders' equity	$ 279,610	$ 280,400

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Consolidated Balance Sheets
Common Shares, no par value (in dollars per share)
Common Shares, issued (in shares)	979,949,668	979,899,668
Common Shares, outstanding (in shares)	979,949,668	979,899,668

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations and Comprehensive Loss
Net revenue	$ 18,930	$ 4,133
Cost of revenue	5,278	1,079
Gross profit	13,652	3,054
Expenses
Research and development	2,578	1,673
Selling, general and administrative	32,997	22,755
Loss from operations	(21,923)	(21,374)
Interest income	2,701	357
Interest expense	(1)	(6)
Gain (loss) on disposal of assets	1	(249)
Gain on extinguishment of debt		533
Other (loss) income	(7)	52
Foreign exchange loss	(152)	(30)
Loss before income taxes	(19,381)	(20,717)
Income tax benefit	2,366	2,333
Net loss	(17,015)	(18,384)
Unrealized losses, change in fair value of available-for-sale securities, net of tax	(869)
Change in foreign currency translation	24	2
Net loss and comprehensive loss	$ (17,860)	$ (18,382)
Weighted average number of common shares - basic (in shares)	979,924,052	956,533,761
Weighted average number of common shares - diluted (in shares)	979,924,052	956,533,761

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Common Stock	Common Stock Subscribed	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Accumulated other comprehensive loss	Total
Balance, amount at Dec. 31, 2020	$ 104,784	$ 460	$ 14,792	$ (68,965)		$ 51,071
Balance (in shares) at Dec. 31, 2020	642,036,228
Stock-based compensation			7,092			7,092
Stock issuance from warrant exercises	$ 44,115		(11,520)			32,595
Stock issuance from warrant exercises (in shares)	201,108,405
Stock issuance costs	$ (14,281)					(14,281)
Stock issuance for financing	$ 199,525					199,525
Stock issuance for financing (in shares)	105,013,158
Stock issuance from exercise of stock options	$ 2,820		(1,051)			$ 1,769
Stock issuance from exercise of stock options (in shares)	7,022,776					7,022,776
Stock redemption	$ 43,999			(32,040)		$ 11,959
Stock redemption (in shares)	24,719,101
Common stock subscribed		$ (460)				(460)
Net (loss)				(18,384)		(18,384)
Other comprehensive income (loss)					$ 2	2
Balance, amount at Dec. 31, 2021	$ 380,962		9,313	(119,389)	2	270,888
Balance (in shares) at Dec. 31, 2021	979,899,668
Stock-based compensation			7,891			7,891
Stock issuance from warrant exercises	$ 11		(3)			8
Stock issuance from warrant exercises (in shares)	50,000
Warrants issued			6,465			6,465
Net (loss)				(17,015)		(17,015)
Other comprehensive income (loss)					(845)	(845)
Balance, amount at Dec. 31, 2022	$ 380,973		$ 23,666	$ (136,404)	$ (843)	$ 267,392
Balance (in shares) at Dec. 31, 2022	979,949,668

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (17,015)	$ (18,384)
Adjustments for
Depreciation	426	265
Amortization - intangible assets	3,616	874
(Gain) loss on disposal of property and equipment	(1)	249
Gain on other assets		(1)
Gain on extinguishment of debt		(533)
Stock-based compensation	7,891	7,092
Non cash portion of rent expense	16	38
Accretion/amortization of available-for-sale securities	(900)
Change in assets and liabilities, net of acquisitions:
Purchased inventory	(4,008)	(2,774)
Prepaid expenses and deposits	(1,465)	(130)
Trade receivables	(283)	(47)
Other receivables	(334)	(165)
Accounts payable and accrued liabilities	3,454	1,412
Accrued income tax	(53)	196
Deferred tax liabilities	(2,356)	(2,528)
Other current liabilities	(184)	201
Customer contract liabilities	51	6
Other liabilities	(525)	(47)
Net cash used in operating activities	(11,670)	(14,276)
Cash flows from investing activities:
Investment in available-for-sale securities	(127,786)
Investment in debt security (at fair value)	(1,000)
Investment in property and equipment	(787)	(147)
Acquisition of intangibles	(239)	(379)
Investment in construction in progress	(1,764)
Investment in acquisitions, net of cash acquired (Assisi, PulseVet, and Revo Squared)	(24,304)	(71,399)
Net cash used in investing activities	(155,880)	(71,925)
Cash flows from financing activities:
Cash proceeds from issuance of common shares and warrants		199,525
Cash received from warrant exercises	8	32,135
Cash paid for shares and warrant issuance costs		(14,270)
Cash received from stock option exercises		1,769
Net cash provided by financing activities	8	219,159
(Decrease) increase in cash and cash equivalents	(167,542)	132,958
Effect of exchange rate changes on cash	(11)	2
Cash and cash equivalents, beginning of year	194,952	61,992
Cash and cash equivalents, end of year	27,399	194,952
Noncash activities:
Change in fair value of available-for-sale securities, net of tax	(869)
Deferred financing fees charged to stock issuance costs		12
Net equity effect of preferred share exchange		(11,961)
Transfer of construction in progress into property and equipment and intangibles	1,955
Transfer of inventory into property and equipment	4,331	798
Supplemental cash flow information:
Interest received	$ 1,588	$ 502

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2022
Nature of Operations
Nature of Operations	1. Nature of Operations Zomedica is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. The impact of the novel strain of coronavirus (“COVID-19”) Since the first quarter of 2020, the world has been impacted by the spread of a novel strain of coronavirus, its variants, and the disease that they cause known as COVID-19. The continued presence of COVID-19 has resulted in changes in the macro-economic environment including disruptions in supply chain, labor disruptions, challenges in manufacturing, challenges selling to customers, declines in customer demand, inflationary pressures, and an impaired ability to access credit and capital markets, among other things. The COVID-19 pandemic materially and adversely affected the development and commercialization of our TRUFORMA platform and the initial five assays. In response to the pandemic, our development partner reduced the number of employees working in its facilities for a period of time which delayed the completion and verification of the five initial TRUFORMA assays and the manufacturing of commercial quantities of the TRUFORMA platform. Veterinary hospitals and clinics that agreed to participate in the validation of our initial TRUFORMA assays either shut down for a period of time or limited their operations to those involving only life-threatening conditions, which we have mitigated to a certain extent with our recent ability to successfully complete remote installations. Potential customers, at times, restricted access to their facilities which affected and may continue to affect our ability to perform on-site demonstrations and other marketing activities. The extent to which the COVID-19 pandemic may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the spread and severity of COVID-19, and the effectiveness of governmental actions in response to the pandemic. To-date, the emergence of new variants has not caused significant modification to business operations. We continue to install remotely if potential customers restrict access to their facilities. We intend to continue development of new assays, both for equine indications of our current and planned assays, and for various additional disease states affecting canine, feline, and equine patients in the future.

Basis of Preparation

Basis of Preparation	12 Months Ended
	Dec. 31, 2022
Basis of Preparation
Basis of Preparation	2. Basis of Preparation Principles of Consolidation The consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries. Intercompany transactions and balances between consolidated businesses have been eliminated. The accounting policies set out below have been applied consistently in the consolidated financial statements. The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Significant Accounting Policies	3. Significant Accounting Policies Basis of Measurement The consolidated financial statements have been prepared on the historical cost basis except as otherwise noted. Business Combinations We account for business combinations in accordance with ASC 805, Business Combinations, if the acquired assets assumed and liabilities incurred constitute a business. We consider acquired companies to constitute a business if the acquired net assets and processes have the ability to create outputs in the form of revenue. For acquired companies constituting a business, we recognize the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognize any excess of total consideration paid over the fair value of the identifiable net assets as goodwill. Estimates and Assumptions In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Functional and Reporting Currencies The functional currency, as determined by management, for our subsidiaries in the United States, Switzerland, and Canada is U.S. dollars, which is also our reporting currency. The functional currency, as determined by management, for our Japanese subsidiary is Japanese Yen. Japanese Yen are translated for financial reporting purposes with translation gains and losses recorded as a component of other comprehensive income or loss. In respect of transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are measured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these transactions are recognized in the consolidated statements of operations and comprehensive loss. Comparative Figures Construction in progress is separately stated in the current period balance sheet for $692 . The consolidated balance sheets for the year ended December 31, 2021 have been adjusted for $420 of construction in progress that was included in intangible assets and property and equipment. This amount has been reclassified to a separate line in the balance sheet to conform to the current year presentation. The change in presentation had no effect on the reported results of operations. These changes in classification do not affect previously reported cash flows from operating activities in the consolidated statements of cash flows. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets held. The Company adopted ASU 2016-13 as of January 1, 2022 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. The Company considered, among other things, historical trends and projected economic / market conditions and determined that the estimate of credit losses was not significantly impacted. Segment Reporting The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company’s reportable segments, reporting of which began in 2021, consist of Diagnostics and Therapeutics. Cash and Cash Equivalents The Company considers all highly liquid securities with an original maturity of three months or less to be cash equivalents. Investment Securities Our investment securities, which are comprised of corporate bonds/notes and US treasuries, are accounted for in accordance with ASC 320, “Investments – Debt and Equity Securities” (“ASC 320”). The company considers all of its securities for which there is a determinable fair market value, and there are no restrictions on the Company’s ability to sell within the next 12 months, as available for sale. We classify these securities as both current and non-current depending on their time to maturity. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported as a component of shareholders’ equity. Accounts Receivable and Allowance for Credit Losses Accounts receivables are recorded net of an allowance for credit losses and have payment terms of 30 days. Our policy for determining the allowance is based on factors that affect collectability, including: (a) historical trends of write-offs, recoveries, and credit losses; (b) the credit quality of our customers; and (c) projected economic and market conditions. As of December 31, 2022, our allowance was $71 and was recorded net in trade receivables. While we believe that our allowance for credit losses is adequate and represents our best estimate as of December 31, 2022, we continue to closely monitor customer liquidity and industry and economic conditions, which may result in changes to these estimates. Inventories Inventories are stated at the lower of cost or net realizable value. The Company utilizes the specific identification and First in, First out ("FIFO") method to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Property and Equipment Property and equipment are carried at historical cost less accumulated depreciation and any accumulated impairment losses. Property and equipment acquired in a business combination are recorded at fair value as of the date of acquisition. Maintenance and repair expenditures that do not improve or extend the life are expensed in the period incurred. Depreciation is recognized so as to write off the cost less their residual values over their useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss. During the quarter ended September 30, 2022, the company changed its policy of recognizing TRUFORMA ® instruments as inventory and reclassified $3,364 to property and equipment, depreciable over 10 years , where they are to remain undepreciated until they are placed with customers. As of the year ended December 31, 2022, the balance related to these undepreciated instruments in property and equipment is $3,487 . Estimated useful lives for the principal asset categories are as follows: ​ ​ ​ ​ Office equipment 3 years Furniture and equipment 5 - 7 years Laboratory equipment 5 - 7 years Machinery and equipment 5 - 10 years Leasehold improvements Over shorter of estimated useful life and lease term ​ Intangible Assets Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life. Costs related to acquired trademarks, tradename, customer relationships and developed technology have been capitalized and amortized over the estimated useful life. Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives and amortization methods are reviewed at the end of each year, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses. ​ ​ ​ ​ ​ E-commerce technology 2 years Computer software and website 3 years Tradename 5 - 19 years Developed technology 10 - 15 years Customer relationships 11 - 19 years Trademarks 15 years ​ Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the sum of estimated undiscounted future cash flows associated with the asset or group of assets is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Share Issue Costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock. Revenue Recognition The Company enters into agreements which may contain multiple promises where customers purchase products, services, or a combination thereof. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires judgment. We determine the transaction price for a contract based on the total consideration we expect to receive in exchange for the transferred goods or services. The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company's contracts with customers are generally comprised of purchase orders for the sale of the point of care instrument, consumable products, and extended warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The extended warranties are also a separate performance obligation, whereby revenue is recognized over time. The nature of the Company’s PulseVet business gives rise to variable consideration, including discounts and applicator (“trode”) returns for refurbishment. Credits are issued for unused shocks on returned trodes, which can be used toward the purchase of replacement trodes. Discounts and the estimated unused shock credits decrease the transaction price, which reduces revenue. Variable consideration related to unused shock credits is estimated using the expected value method, which estimates the amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration are based upon historical experience and known trends. These estimated credits are nonrefundable and may only be used towards the purchase of future trode refurbishments. This practice encourages refurbishment purchase prior to complete utilization of the previous trode, so the customer will always have a trode on hand with ample capacity to perform treatments. At times the Company receives consideration prior to when the performance obligation is completed, giving rise to a contract liability. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority. Disaggregated revenue for the years ended December 31, 2022 and 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diagnostics ​ ​ Therapeutics ​ ​ ​ 2022 ​ ​ 2021 ​ ​ 2022 ​ ​ 2021 Consumables ​ $ 391 ​ $ 125 ​ $ 2,072 ​ $ - Instruments ​ ​ - ​ ​ - ​ ​ 7,269 ​ ​ 1,793 Trodes ​ ​ - ​ ​ - ​ ​ 8,681 ​ ​ 2,073 Other (e.g., Warranty and Repairs) ​ ​ - ​ ​ - ​ ​ 517 ​ ​ 142 Total revenue ​ $ 391 ​ $ 125 ​ $ 18,539 ​ $ 4,008 ​ ​ Cost of goods sold consists of materials, labor, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of revenue. Research and Development Research and development costs related to continued research and development programs are expensed as incurred. Stock-based Compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of the Company’s stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, on a tax jurisdictional basis. The Company files income tax returns in Canada and the province of Alberta and its subsidiaries file income tax returns in the United States and various states, including in Michigan where the Company’s headquarters are located. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized. The Company assesses the likelihood of the financial statement effect of an uncertain tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in jurisdictions such as the United States and Canada. The Company recognizes tax-related interest and penalties, if any, as a component separate from income tax expense . Comprehensive Loss The Company follows ASC topic 220. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders’ equity. The Company has recorded a currency translation adjustment associated with its Japanese subsidiary. Loss Per Share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options is excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during fiscal 2022 and 2021 were not included in the computation of diluted EPS because the Company has incurred a loss for the years ended December 31, 2022 and 2021 and the effect would be anti-dilutive.

Critical Accounting Judgments a

Critical Accounting Judgments and Key Sources of Estimation Uncertainty	12 Months Ended
	Dec. 31, 2022
Critical Accounting Judgments and Key Sources of Estimation Uncertainty
Critical Accounting Judgments and Key Sources of Estimation Uncertainty	4. Critical Accounting Judgments and Key Sources of Estimation Uncertainty The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Critical areas of estimation and judgements in applying accounting policies include the following: Intangible Assets and Business Combinations Assets acquired and liabilities assumed as part of a business combination are recognized at their acquisition date fair values. In determining these fair values, we utilize various forms of the income, cost, and market approaches depending on the asset or liability being valued. We use a discounted cash flow model to measure the trade names, customer relationship, and technology assets. The estimation of fair value requires significant judgment related to future net cash flows based on assumptions related to revenue and EBITDA growth rates, discount rates, and attrition factors. Inputs are generally determined by taking into account competitive trends, market comparisons, independent appraisals, and historical data, among other factors, and are supplemented by current and anticipated market conditions. Impairment Testing We evaluate goodwill for impairment annually or more frequently when an event occurs or circumstances change indicating the carrying value may not be recoverable. When testing goodwill for impairment, we may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. During a qualitative analysis, we consider the impact of changes, if any, to the following factors: macroeconomic, industry and market factors; cost factors; changes in overall financial performance; and any other relevant events and uncertainties impacting a reporting unit. If our qualitative assessment indicates a goodwill impairment is more likely than not, we perform additional quantitative analyses. We may also elect to skip the qualitative testing and proceed directly to the quantitative testing. For reporting units where a quantitative analysis is performed, we perform a test measuring the fair values of the reporting units and comparing them to their aggregate carrying values, including goodwill. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill. We estimate the fair values of our reporting units using a discounted cash flow method or a weighted combination of discounted cash flows and a market-based method. The discounted cash flow method includes assumptions about a wide variety of internal and external factors. Significant assumptions used in the discounted cash flow method include financial projections of free cash flow, including revenue trends, medical costs trends, operating productivity, income taxes and capital levels; long-term growth rates for determining terminal value beyond the discretely forecasted periods; and discount rates. Financial projections and long-term growth rates used for our reporting units will be consistent with, and use inputs from, our internal long-term business plan and strategies. Discount rates will be determined for each reporting unit and include consideration of the implied risk inherent in their forecasts. Our most significant estimate in the discount rate determinations involves our adjustments to the peer company weighted average costs of capital reflecting reporting unit-specific factors. We do not make any adjustments to decrease a discount rate below the calculated peer company weighted average cost of capital for any reporting unit. Company-specific adjustments to discount rates are subjective and thus are difficult to measure with certainty. The passage of time and the availability of additional information regarding areas of uncertainty with respect to the reporting units’ operations could cause these assumptions to change in the future. Additionally, as part of our quantitative impairment testing, we perform various sensitivity analyses on certain key assumptions, such as discount rates, cash flow projections, and peer company multiples to analyze the potential for a material impact. The market-based method requires determination of an appropriate peer group whose securities are traded on an active market. The peer group is used to derive market multiples to estimate fair value. Valuation and Payback of Property and Equipment Our Diagnostics segment purchases instruments and places them in fixed assets, where they remain, undepreciated, until they are placed with our customers under the agreement that they will repeatedly purchase assays (tests) which are utilized in the instrument. Each instrument placed in the portfolio represents an asset that we own. An estimate is made of the anticipated future revenue over the life of the instrument, based on the sale of assays, which is typically ten years. If the payback period of the initial investment in the asset is less than the ten-year life of the asset, we conclude that the assets have been properly recorded, and no write-down is necessary. We rely on third-party data that considers various data points and assumptions, including, but not limited to, the expected volume of assays which will be sold, anticipated growth rates and placements of instruments. Realization of the anticipated revenue is dependent on the current assumptions and forecasted models. Revenue Recognition and Liabilities Due to Customers The nature of the Company’s business gives rise to variable consideration, including discounts and applicator (“trode”) returns for refurbishment. Credits are issued for unused shocks on returned trodes, which can be used toward the purchase of replacement trodes. Discounts and the estimated unused shock credits decrease the transaction price, which reduces revenue. Variable consideration related to unused shock credits is estimated using the expected value method, which estimates the amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration are estimated based upon historical experience and known trends. These estimated credits are non-refundable and may only be used towards the purchase of future trode refurbishments. This practice encourages refurbishment purchase prior to complete utilization of the previous trode, so the customer will always have a trode at hand with ample capacity to perform treatments. ​

Investment Securities

Investment Securities	12 Months Ended
	Dec. 31, 2022
Investment Securities
Investment Securities	5. Investment Securities The following represents the Company’s investment securities as of December 31, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition Cost ​ ​ Accretion / (Amortization) ​ ​ Unrealized Gain / (Loss) ​ ​ Estimated Fair Value Commercial paper ​ $ 30,634 ​ $ 471 ​ $ (139) ​ $ 30,966 Corporate notes / bonds ​ ​ 44,115 ​ ​ 192 ​ ​ (547) ​ ​ 43,760 Debt security ​ ​ 1,000 ​ ​ - ​ ​ - ​ ​ 1,000 Money market funds ​ ​ 10,196 ​ ​ - ​ ​ - ​ ​ 10,196 U.S. govt. agencies ​ ​ 46,223 ​ ​ 85 ​ ​ (230) ​ ​ 46,078 U.S. treasuries ​ ​ 15,629 ​ ​ 99 ​ ​ (145) ​ ​ 15,583 Total investment securities ​ $ 147,797 ​ $ 847 ​ $ (1,061) ​ $ 147,583 ​ ​ Accrued interest receivable related to the above investment securities amounted to $677 and is included within Other Receivables on our consolidated balance sheet. Contractual maturities of investment securities as of December 31, 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition Cost ​ ​ Estimated Fair Value Original maturities of 90 days or less ​ $ 19,127 ​ $ 19,178 Original maturities of 91-365 days ​ ​ 87,528 ​ ​ 87,693 Original maturities of 366+ days ​ ​ 41,142 ​ ​ 40,712 Total investment securities ​ $ 147,797 ​ $ 147,583 ​

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Fair Value Measurements
Fair value Measurements	6. Fair Value Measurements In accordance with FASB ASC 820, “Fair Value Measurements and Disclosures,” (“ASC 820”), the Company measures its cash and cash equivalents and investments at fair value on a recurring basis. The company also measures certain assets and liabilities at fair value on a non-recurring basis when applying acquisition accounting. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. ​ Level 3: Unobservable data points for the assets or liability, and include situations where there is little, if any, market activity for the asset or liability. Valuations based on inputs that are unobservable and Cash and cash equivalents, accounts receivable, and accounts payable: Available-for-sale securities: Earnout liability: Included within these available-for-sale securities is a $1M convertible note associated with Structured Monitoring Products, Inc.’s (“SMP”) VetGuardian™ line. There were no unrealized gains or losses recorded and no other than temporary impairments recognized as of December 31, 2022. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 ​ ​ Level 2 ​ ​ Level 3 ​ ​ Estimated Fair Value Commercial paper ​ $ - ​ $ 30,966 ​ $ - ​ $ 30,966 Corporate notes / bonds ​ ​ - ​ ​ 43,760 ​ ​ - ​ ​ 43,760 Debt security ​ ​ - ​ ​ - ​ ​ 1,000 ​ ​ 1,000 Money market funds ​ ​ 10,196 ​ ​ - ​ ​ - ​ ​ 10,196 U.S. govt. agencies ​ ​ 46,078 ​ ​ - ​ ​ - ​ ​ 46,078 U.S. treasuries ​ ​ 15,583 ​ ​ - ​ ​ ​ ​ ​ 15,583 Total investment securities ​ $ 71,857 ​ $ 74,726 ​ $ 1,000 ​ $ 147,583 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash & Cash Equiv. ​ ​ Available- For-Sale (Current) ​ ​ Available- For-Sale (Non-Current) ​ ​ Estimated Fair Value Commercial paper ​ $ - ​ $ 30,966 ​ $ - ​ $ 30,966 Corporate notes / bonds ​ ​ - ​ ​ 24,272 ​ ​ 19,488 ​ ​ 43,760 Debt security ​ ​ - ​ ​ - ​ ​ 1,000 ​ ​ 1,000 Money market funds ​ ​ 10,196 ​ ​ - ​ ​ - ​ ​ 10,196 U.S. govt. agencies ​ ​ 8,982 ​ ​ 23,597 ​ ​ 13,499 ​ ​ 46,078 U.S. treasuries ​ ​ - ​ ​ 8,858 ​ ​ 6,725 ​ ​ 15,583 Total investment securities ​ $ 19,178 ​ $ 87,693 ​ $ 40,712 ​ $ 147,583 ​ ​

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2022
Business Combinations
Business Combinations	7. Business Combinations All of the Company’s acquisitions of business have been accounted for under ASC 805, Business Combinations. Accordingly, the assets of the acquired companies reflect the fair values and have been included in the Company’s Condensed Financial Statements from their respective dates of acquisition. The results of operations of Pulse Veterinary Technologies, LLC, Revo Squared LLC, and Assisi Animal Health, LLC have been included in the Company’s Condensed Financial Statements since the dates of acquisition on October 1, 2021, June 14, 2022, and July 15, 2022, respectively. 2022 Acquisitions Asset Purchase Agreement with Assisi Animal Health LLC On July 15, 2022, Zomedica Corp. and its wholly owned subsidiary Zomedica Inc. entered into an Asset Purchase Agreement with Assisi Animal Health LLC (“Assisi”), its wholly owned subsidiary, AAH Holdings LLC, and certain of Assisi’s members pursuant to which Zomedica Inc. agreed to acquire substantially all of the assets of Assisi. The Sellers are in the business of developing, manufacturing, marketing, distributing and selling animal health products which use targeted Pulsed Electromagnetic Field (PEMF) therapy to decrease pain and inflammation, accelerate healing, and reduce anxiety that include the Assisi Loop ® ® ® ® Zomedica Inc. paid Assisi a purchase price of $18,293 in cash, which was subject to adjustments based on, among other things, the value of Assisi’s inventory and prepaid expenses at the closing of the acquisition. A portion of the purchase price ($1,400) was deposited into a third-party escrow account to support AAH Holdings LLC and certain of Assisi’s members’ indemnification obligation under the Purchase Agreement, of which $500 was released and $900 will be distributed to Assisi on the 18-month As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $14,329 was recorded in connection with this acquisition, which will be deductible for US tax purposes. The goodwill largely results from our ability to market and sell their respective products and services through our established customer base. The Company made a preliminary allocation of the purchase price for Assisi Animal Health LLC’s asset base based on its understanding of the fair value of the acquired assets and assumed liabilities. As the Company continues to obtain additional information about these assets and liabilities, including intangible asset appraisals, inventory valuation, and accrued expenses, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the acquisition period. The following table summarizes the preliminary acquisition date fair values of the assets acquired and liabilities assumed and subsequent initial period adjustments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial Measurement ​ ​ ​ ​ Allocation of ​ Period ​ Updated ​ Consideration Adjustments Allocation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Inventory, net ​ $ 220 ​ $ — ​ $ 220 Prepaid expenses and deposits ​ 271 ​ — ​ 271 Other receivables ​ ​ 406 ​ ​ (206) ​ ​ 200 Right of use asset ​ ​ — ​ ​ 260 ​ ​ 260 Intangible Assets (estimated useful life) ​ ​ ​ ​ ​ ​ ​ ​ E-commerce technology ( 2 years) ​ 200 ​ — ​ 200 Trade name ( 5 years) ​ 300 ​ — ​ 300 Developed technology ( 10 years) ​ 4,500 ​ — ​ 4,500 Customer relationships ( 19 years) ​ 2,800 ​ — ​ 2,800 Total assets acquired ​ 8,697 ​ 54 ​ 8,751 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current portion of lease obligations ​ ​ — ​ 49 ​ 49 Non current portion of lease obligations ​ ​ — ​ 211 ​ 211 Other non current liabilities ​ ​ 45 ​ — ​ 45 Total liabilities assumed ​ 45 ​ 260 ​ 305 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired, excluding goodwill ​ 8,652 ​ (206) ​ 8,446 Goodwill ​ 14,329 ​ 206 ​ 14,535 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired ​ $ 22,981 ​ $ — ​ $ 22,981 ​ ​ ​ ​ ​ ​ ​ Cash ​ $ 18,293 Fair value of warrants ​ $ 4,688 Total ​ $ 22,981 ​ ​ The following table provides unaudited proforma financial information, prepared in accordance with Topic 805, for the years ended December 31, 2022 and 2021, as if Assisi had been acquired as of January 1, 2021. Proforma results do not include the effect of any synergies anticipated to be achieved from the acquisition, and accordingly, are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the date indicated or that may result in the future. ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2022 ​ 2021 Net Revenue $ 21,838 ​ $ 8,841 Net Losses $ (18,038) ​ $ (18,822) ​ The proforma amounts have been calculated by including the results of Assisi, and adjusting the combined results to give effect to the following, as if the acquisitions had been consummated on January 1, 2021, together with the consequential tax effects thereon: ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2022 ​ 2021 Adjustments to net revenues ​ ​ ​ ​ ​ Assisi preacquisition revenues $ 2,908 ​ $ 4,708 Adjustments to net income ​ ​ ​ ​ ​ Assisi preacquisition net losses $ (639) ​ $ (438) ​ ​ Asset Purchase Agreement with Revo Squared LLC On June 14, 2022, Zomedica Corp. and its wholly owned subsidiary Zomedica Inc. entered into an Asset Purchase Agreement with Revo Squared LLC (“Revo Squared”) and its majority member pursuant to which Zomedica Inc. agreed to acquire substantially all of the assets of Revo Squared. Revo Squared, based in Marietta, Georgia, was in the business of developing, manufacturing, marketing, distributing, and selling diagnostic imaging products and services for use in animal health, including its SuperView™, Sonoview™ Color ultrasound, Sonoview Mini/Mini Plus ultrasound, and Microview™ product offerings. On July 1, 2022, the parties consummated the acquisition. At the closing, Zomedica Inc. paid Revo Squared a base purchase price of $6,011 in cash, which was subject to adjustments based on the amount of Revo Squared’s working capital at the closing. On this date, $500 of the purchase price was deposited into a third-party escrow account for a period of 15 months to support Revo Squared’s indemnification obligation under the Purchase Agreement. The Company also issued to Revo Squared a ten-year warrant to purchase an aggregate of 10,000,000 of the Company’s common shares at a per share exercise price equal to $0.2201. The warrants may be exercised on a cash or cashless basis, at the election of the warrant holder. In addition, Zomedica Inc. has agreed to pay Revo Squared aggregate earn-out payments of up to $4,000 based on the achievement of milestones related to future net sales from Revo Squared Products. One As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $6,528 was recorded in connection with this acquisition, which will be deductible for US tax purposes. The goodwill largely results from our ability to market and sell their respective products and services through our established customer base. The Company made a preliminary allocation of the purchase price for Revo Squared’s asset base based on its understanding of the fair value of the acquired assets and assumed liabilities. As the Company continues to obtain additional information about these assets and liabilities, including intangible asset appraisals, inventory valuation, and accrued expenses, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the acquisition period. ​ The following table summarizes the preliminary acquisition date fair values of the assets acquired and liabilities assumed and subsequent initial period adjustments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial Measurement ​ ​ ​ ​ Allocation of ​ Period ​ Updated ​ Consideration Adjustments Allocation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade receivables, net ​ $ 8 ​ $ — ​ $ 8 Prepaid expenses and deposits ​ 10 ​ — ​ 10 Intangible Assets (estimated useful life) ​ ​ ​ ​ ​ ​ ​ ​ Trade name ( 5 years) ​ 200 ​ — ​ 200 Developed technology ( 10 years) ​ 2,300 ​ — ​ 2,300 Customer relationships ( 16 years) ​ 1,200 ​ — ​ 1,200 Total assets acquired ​ 3,718 ​ — ​ 3,718 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnout liabilities ​ 2,458 ​ (458) ​ 2,000 Total liabilities assumed ​ 2,458 ​ (458) ​ 2,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired, excluding goodwill ​ 1,260 ​ 458 ​ 1,718 Goodwill ​ 6,528 ​ (458) ​ 6,070 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired ​ $ 7,788 ​ $ — ​ $ 7,788 ​ ​ ​ ​ ​ ​ ​ Cash ​ $ 6,011 Fair value of warrants ​ $ 1,777 Total ​ $ 7,788 ​ ​ 2021 Acquisitions ​ Acquisition of PulseVet On October 1, 2021, Zomedica Inc., a wholly owned subsidiary of Zomedica Corp. (the “Company”), entered into a Stock Purchase Agreement with Branford PVT Mid-Hold, LLC pursuant to which Zomedica Inc. acquired 100% of the capital stock of Branford PVT Acquiror, Inc., a Delaware corporation (“BPA”). BPA was a holding company whose direct and indirect wholly owned subsidiaries included Pulse Veterinary Technologies, LLC (“PulseVet”), which, together with its consolidated subsidiaries, was a leading provider of noninvasive shock wave therapy treatment devices to the veterinary industry (the “Acquisition”). BPA and PulseVet were merged into Zomedica Inc. on July 1, 2022. The purchase price for the acquisition was $71,929 in cash. As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $44,915 was recorded in connection with this acquisition, none of which will be deductible for U.S tax purposes. The goodwill largely results from our ability to market and sell the PulseVet Technology through our established customer base. The Company finalized the allocation of the purchase price for PulseVet as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial Measurement ​ ​ ​ ​ Allocation of ​ Period ​ Updated ​ Consideration Adjustments Allocation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 526 ​ $ 3 ​ $ 529 Trade receivables ​ 269 ​ — ​ 269 Inventory ​ 840 ​ 31 ​ 871 Prepaid expenses and deposits ​ 365 ​ — ​ 365 Other receivables ​ — ​ 150 ​ 150 Property and equipment ​ 125 ​ — ​ 125 Intangible Assets (estimated useful life) ​ ​ ​ ​ ​ ​ ​ ​ Customer relationships ( 11 years) ​ 22,650 ​ — ​ 22,650 Developed technology ( 15 years) ​ 8,650 ​ — ​ 8,650 Trade name ( 19 years) ​ 2,350 ​ — ​ 2,350 Other Assets ​ 69 ​ 265 ​ 334 Total assets acquired ​ 35,844 ​ 449 ​ 36,293 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts payable and accrued liabilities ​ 1,112 ​ (543) ​ 569 Income tax payable ​ 44 ​ — ​ 44 Deferred revenue ​ 61 ​ — ​ 61 Liability for contracts with customers ​ 332 ​ — ​ 332 Deferred tax liabilities ​ 7,138 ​ (814) ​ 6,324 Other non current liabilities ​ 143 ​ 265 ​ 408 Total liabilities assumed ​ 8,830 ​ (1,092) ​ 7,738 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired, excluding goodwill ​ 27,014 ​ 1,541 ​ 28,555 Goodwill ​ 44,915 ​ (1,541) ​ 43,374 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired ​ $ 71,929 ​ $ — ​ $ 71,929 ​

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Inventory
Inventory	8. Inventory Inventory details are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ December 31, 2021 ​ ​ Diagnostics Therapeutics Consolidated Diagnostics Therapeutics Consolidated Raw Materials ​ $ — ​ $ 1,685 ​ $ 1,685 ​ $ — ​ $ 890 ​ $ 890 Finished Goods ​ — ​ 182 ​ 182 ​ — ​ 140 ​ 140 Purchased Inventory ​ 919 ​ — ​ 919 ​ 1,848 ​ — ​ 1,848 Total ​ 919 ​ 1,867 ​ 2,786 ​ 1,848 ​ 1,030 ​ 2,878 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Reserves ​ (18) ​ (22) ​ (40) ​ (9) ​ (21) ​ (30) Net inventory ​ $ 901 ​ $ 1,845 ​ $ 2,746 ​ $ 1,839 ​ $ 1,009 ​ $ 2,848 ​

Prepaid Expenses and Deposits

Prepaid Expenses and Deposits	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses and Deposits.
Prepaid Expenses and Deposits	9. Prepaid Expenses and Deposits ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 Deposits ​ $ 1,886 ​ $ 1,340 Prepaid marketing ​ 114 ​ 83 Prepaid insurance ​ 614 ​ 599 Prepaid taxes ​ 753 ​ — Other ​ 620 ​ 214 Total prepaid expenses and deposits ​ $ 3,987 ​ $ 2,236 ​

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property and Equipment
Property and Equipment	10. Property and Equipment ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ Machinery and office equipment ​ $ 6,487 ​ $ 1,392 Furniture and equipment ​ 111 ​ 110 Laboratory equipment ​ 249 ​ 225 Leasehold improvements ​ 1,239 ​ 287 ​ ​ 8,086 ​ 2,014 ​ ​ ​ ​ ​ ​ ​ Accumulated depreciation and amortization ​ 1,277 ​ 884 Net property and equipment ​ $ 6,809 ​ $ 1,130 ​ Depreciation expense for the year ended December 31, 2022 and 2021 was $426 and $265, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Intangible Assets
Intangible Assets	11. Intangible Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ Computer software ​ $ 350 ​ $ 28 Customer relationships ​ 26,651 ​ 22,650 Technology ​ 15,650 ​ 8,650 Trademarks ​ 16 ​ 16 Tradename ​ 2,850 ​ 2,350 Website ​ 962 ​ 546 ​ ​ 46,479 ​ 34,240 ​ ​ ​ ​ ​ ​ ​ Accumulated amortization ​ 4,680 ​ 1,064 Net intangibles ​ $ 41,799 ​ $ 33,176 ​ The estimated future amortization of intangible assets is as follows: ​ ​ ​ ​ 2023 $ 4,098 2024 ​ 4,067 2025 ​ 3,903 2026 ​ 3,781 2027 and beyond ​ 25,950 Total ​ $ 41,799 ​ Amortization expense for the year ended December 31, 2022 and 2021 was $3,616 and $874, respectively.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	12. Leases On February 1, 2021 the Company downsized its office space and modified its existing lease with Wickfield Phoenix LLC. The new lease period was for 48 months, commencing on February 1, 2021 and ending on January 31, 2025 with a monthly rent payment of $12 for the first two months and escalating to $31 over the lease period. The carrying value of the right of use asset was $1,258 upon modification using the Company's incremental borrowing rate of 3.95%. During the period ending March 31, 2021 the Company recorded a gain on right-of-use asset of $24 in the consolidated statements of comprehensive loss. On September 15, 2021, the Company entered into an additional lease with Wickfield Phoenix LLC for warehousing space. The new lease period is for 41 months, commencing on September 15, 2021, and ending on January 31, 2025, with a monthly rent payment of $5 for the first month and escalating to $10 over the lease period. The Company recorded a right-of-use asset and corresponding lease liability for $366 using the Company's incremental borrowing rate of 3.95%. On April 1, 2022, the Company entered into an agreement with ULF Northfield Business Center LLC to lease 12,400 square feet of office and warehouse space. The lease period is for 61 months beginning on April 1, 2022, with a monthly rent payment of $9 for the first twelve months and escalating to $11 per month over the lease period. The Company recorded a right-of-use asset and corresponding lease liability for $546 using an incremental borrowing rate of 3.95%. On July 1, 2022, as part of the Revo Squared Purchase, the Company assumed an agreement with Lebow 1031 Legacy, LLC to lease 4,626 square feet of office space. The remaining lease period assumed at the time of the agreement is for 18 months beginning on July 1, 2022 and lasting through December of 2023. The lease has a monthly rent payment of $4 per month over the lease period. The Company recorded a right-of-use asset and corresponding lease liability for $67 using an incremental borrowing rate of 7.00%. On July 15, 2022, as part of the Assisi asset purchase agreement, the Company assumed a license agreement pursuant to a lease agreement between The Wheelership LLC and The Realty Associates Fund XII portfolio, L.P., whereby Assisi sublet 5,185 square feet of warehousing space. The remaining lease period assumed at the time of the agreement is for 52 months beginning on August 16, 2022 and lasts through November of 2026. The lease has a rent payment of $4 for the first month and escalates to $6 per month over the lease period. The Company recorded a right-of-use asset and corresponding lease liability for $260 using an incremental borrowing rate of 7.00%. For the years ended December 31, 2021 and December 31, 2022, the Company recognized $411 and $661 in rent expense inclusive of common area maintenance (CAM) charges, insurance, and tax with $95 and $62 recorded in research and development expenses and $316 and $599 recorded in general and administrative expense in the consolidated statements of comprehensive loss. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ 2022 ​ 2021 Right-of-use asset ​ Cost ​ ​ Aggregate lease commitments ​ $ 2,759 ​ $ 1,779 Less: impact of present value ​ (262) ​ ​ (155) Balance ​ $ 2,497 ​ $ 1,624 ​ ​ ​ ​ ​ ​ ​ Reduction in right-of-use asset ​ ​ ​ Straight line amortization ​ 946 ​ ​ 346 Interest ​ (114) ​ ​ (42) Balance ​ $ 832 ​ $ 304 ​ ​ ​ ​ ​ ​ ​ Net book value as at: ​ ​ ​ ​ ​ ​ Balance ​ $ 1,665 ​ $ 1,320 ​ ​ ​ ​ ​ ​ ​ Lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additions ​ $ 2,520 ​ $ 1,647 Payments ​ (896) ​ ​ (310) Interest ​ 114 ​ ​ 42 Total lease liabilities ​ $ 1,738 ​ $ 1,379 ​ ​ ​ ​ ​ ​ ​ Current portion of lease liabilities ​ 641 ​ ​ 415 Long term portion of lease liabilities ​ 1,097 ​ ​ 964 Total lease liabilities ​ $ 1,738 ​ $ 1,379 ​ Total remaining undiscounted lease liabilities related to the above lease are as follows: ​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ 706 2024 ​ 679 2025 ​ 237 2026 ​ ​ 197 2027 ​ ​ 44 Total lease payments ​ $ 1,863 Less imputed interest ​ ​ 125 Total ​ $ 1,738 ​ ​ Our weighted-average remaining lease term and discount rate are as follows: ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2022 Weighted-average remaining lease term ​ ​ 2.9 years Weighted-average discount rate ​ ​ 4.5% ​

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2022
Common Stock.
Common Stock	13. Common Stock On February 8, 2021, the Company completed a sale of 91,315,790 common shares at an offering price of $1.90 per share. The Company also granted the underwriter a 30-day option to purchase up to 13,697,368 additional common shares at the public offering price. The Company raised $199,525 in gross proceeds as part of the offering. The Company recorded $199,525 as the value of common shares under common shares. The direct cash costs related to the issuance of the common shares and warrants issued in February 2021 were $14,281. These direct costs were recorded as an offset against the statement of shareholders’ equity with the entirety recorded under common shares.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Stock-Based Compensation
Stock-Based Compensation	14. Stock-Based Compensation During the year ended December 31, 2022, the Company issued 47,292,219 stock options, each option entitling the holder to purchase one common share of the Company. The options vest over a period of four years and have an expiration period of ten years. During the year ended December 31, 2021, the Company issued 35,471,000 stock options, each option entitling the holder to purchase one common share of the Company. The options vest over a period of four years and have an expiration period of five years. During the year ended December 31, 2021, 7,022,776 options were exercised, and the Company received $1,769 in cash receipts and reclassified $1,051 of additional paid in capital to common stock due to the exercise of stock options. No options were exercised in 2022. The continuity of stock options are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Weighted Avg ​ ​ ​ Options ​ Exercise Price ​ Balance at December 31, 2021 50,717,724 $ 0.4466 Stock options granted 47,292,219 ​ ​ 0.2692 ​ Stock options forfeited 4,300,000 ​ ​ 0.6108 ​ Vested stock options expired 9,597,500 ​ ​ 0.2601 ​ Balance at December 31, 2022 84,112,443 ​ $ 0.3602 ​ Vested at December 31, 2022 23,850,099 ​ $ 0.3698 ​ ​ As of December 31, 2022, details of the issued and outstanding stock options are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Avg ​ ​ ​ ​ Number of Options ​ Number of ​ Unvested ​ Remaining Life ​ ​ ​ ​ Issued ​ Vested Options ​ Options ​ Outstanding Grant Date ​ Exercise Price ​ and Outstanding ​ Outstanding ​ Outstanding ​ (Years) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 14, 2020 0.19 1,133,557 837,182 296,375 2.20 July 9, 2020 0.18 175,000 131,250 43,750 2.52 August 25, 2020 0.13 20,000 10,000 10,000 2.65 October 1, 2020 0.11 266,667 191,667 75,000 2.75 October 20, 2020 0.09 20,000 15,000 5,000 2.81 December 31, 2020 0.23 15,742,500 13,002,500 2,740,000 3.00 February 26, 2021 1.87 100,000 100,000 — 3.16 March 1, 2021 2.06 200,000 100,000 100,000 3.17 March 8, 2021 1.88 100,000 100,000 — 3.19 March 15, 2021 2.49 100,000 100,000 — 3.21 May 12, 2021 0.78 3,400,000 1,700,000 1,700,000 3.36 May 14, 2021 0.75 3,200,000 850,000 2,350,000 3.37 August 11, 2021 0.57 525,000 225,000 300,000 3.61 August 18, 2023 0.50 200,000 50,000 150,000 3.63 August 23, 2021 0.50 25,000 25,000 — 3.65 September 13, 2021 0.57 800,000 200,000 600,000 3.70 October 1, 2021 0.58 12,412,500 3,112,500 9,300,000 3.75 January 3, 2022 ​ 0.36 100,000 — 100,000 4.01 January 4, 2022 ​ 0.35 200,000 — 200,000 4.01 January 14, 2022 ​ 0.35 200,000 — 200,000 4.04 January 16, 2022 ​ 0.35 50,000 — 50,000 4.05 January 18, 2022 ​ 0.35 100,000 — 100,000 4.05 February 14, 2022 ​ 0.30 200,000 — 200,000 4.13 February 21, 2022 ​ 0.37 200,000 — 200,000 4.15 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Avg ​ ​ ​ ​ Number of Options ​ Number of ​ Unvested ​ Remaining Life ​ ​ ​ ​ Issued ​ Vested Options ​ Options ​ Outstanding Grant Date ​ Exercise Price ​ and Outstanding ​ Outstanding ​ Outstanding ​ (Years) February 25, 2022 ​ 0.35 12,100,000 — 12,100,000 4.16 March 30, 2022 ​ 0.35 200,000 — 200,000 4.25 April 1, 2022 ​ 0.34 200,000 — 200,000 4.25 April 6, 2022 ​ 0.32 100,000 — 100,000 4.27 April 11, 2022 ​ 0.31 75,000 — 75,000 4.28 May 2, 2022 ​ 0.25 300,000 — 300,000 4.34 May 9, 2022 ​ 0.21 700,000 — 700,000 4.36 May 11, 2022 ​ 0.20 400,000 — 400,000 4.36 May 16, 2022 ​ 0.23 100,000 — 100,000 4.38 May 31, 2022 ​ 0.24 500,000 — 500,000 4.42 June 1, 2022 ​ 0.25 500,000 — 500,000 4.42 June 6, 2022 ​ 0.26 200,000 — 200,000 4.43 June 13, 2022 ​ 0.24 200,000 — 200,000 4.45 June 17, 2022 ​ 0.24 3,100,000 3,100,000 — 4.46 July 1, 2022 ​ 0.21 350,000 — 350,000 4.50 July 5, 2022 ​ 0.22 200,000 — 200,000 4.51 July 6, 2022 ​ 0.26 100,000 — 100,000 4.52 July 25, 2022 ​ 0.25 200,000 — 200,000 4.57 August 1, 2022 ​ 0.28 100,000 — 100,000 4.59 August 5, 2022 ​ 0.34 2,850,000 — 2,850,000 4.60 August 8, 2022 ​ 0.39 100,000 — 100,000 4.61 August 17, 2022 ​ 0.31 200,000 — 200,000 4.63 August 19, 2022 ​ 0.27 200,000 — 200,000 4.64 August 22, 2022 ​ 0.27 400,000 — 400,000 4.64 August 29, 2022 ​ 0.27 400,000 — 400,000 4.66 August 31, 2022 ​ 0.25 800,000 — 800,000 4.67 September 21, 2022 ​ 0.23 200,000 — 200,000 4.73 September 23, 2022 ​ 0.21 400,000 — 400,000 4.73 September 26, 2022 ​ 0.22 300,000 — 300,000 4.74 October 4, 2022 ​ 0.22 4,000,000 — 4,000,000 4.76 November 3, 2022 ​ 0.23 200,000 — 200,000 4.84 November 7, 2022 ​ 0.24 500,000 — 500,000 4.85 November 8, 2022 ​ 0.24 4,950,000 — 4,950,000 4.86 November 9, 2022 ​ 0.23 300,000 — 300,000 4.86 November 14, 2022 ​ 0.24 350,000 — 350,000 4.87 November 21, 2022 ​ 0.21 50,000 — 50,000 4.89 December 1, 2022 ​ 0.21 100,000 — 100,000 4.92 December 9, 2022 ​ 0.19 8,717,219 — 8,717,219 4.94 Balance at December 31, 2022 ​ 84,112,443 23,850,099 60,262,344 ​ The Company calculates volatility of stock-based compensation using the historical price of the Company’s stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. ​ The fair value of options granted during the year ended December 31, 2022 was estimated using the Black-Scholes option pricing model to determine the fair value of options granted using the following assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Grant Date Volatility ​ Risk-Free Interest Rate ​ Expected Life (In Years) ​ Dividend Yield ​ ​ ​ Common Share Price ​ ​ Strike Price Forfeiture Rate ​ February 26, 2021 ​ 117 % ​ 0.95 % ​ 10 ​ ​ 0 % ​ $ 1.87 ​ $ 1.87 ​ 0 % March 1, 2021 ​ 117 ​ ​ 0.92 ​ ​ 10 ​ ​ 0 ​ ​ ​ 2.06 ​ ​ 2.06 ​ 0 ​ March 8, 2021 ​ 117 ​ ​ 1.07 ​ ​ 10 ​ ​ 0 ​ ​ ​ 1.88 ​ ​ 1.88 ​ 0 ​ March 15,2021 ​ 117 ​ ​ 1.06 ​ ​ 5.75 ​ ​ 0 ​ ​ ​ 2.49 ​ ​ 2.49 ​ 0 ​ May 12, 2021 ​ 118 ​ ​ 1.11 ​ ​ 6.21 - 6.22 ​ ​ 0 ​ ​ ​ 0.78 ​ ​ 0.78 ​ 0 ​ May 14, 2021 ​ 118 ​ ​ 1.06 ​ ​ 5.75 ​ ​ 0 ​ ​ ​ 0.76 ​ ​ 0.75 ​ 0 ​ May 14, 2021 ​ 118 ​ ​ 1.06 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.75 ​ ​ 0.75 ​ 0 ​ August 11, 2021 ​ 116 ​ ​ 0.96 ​ ​ 6.18 - 6.25 ​ ​ 0 ​ ​ ​ 0.56 ​ ​ 0.57 ​ 0 ​ August 18,2021 ​ 116 ​ ​ 0.93 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.50 ​ ​ 0.50 ​ 0 ​ August 23, 2021 ​ 116 ​ ​ 0.92 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.50 ​ ​ 0.50 ​ 0 ​ October 1, 2021 ​ 116 ​ ​ 1.10 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.57 ​ ​ 0.58 ​ 0 ​ January 3, 2022 ​ 114 ​ ​ 1.50 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.36 ​ ​ 0.36 ​ 0 ​ January 4, 2022 ​ 114 ​ ​ 1.47 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ January 14, 2022 ​ 114 ​ ​ 1.64 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ January 16, 2022 ​ 114 ​ ​ 1.73 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ January 18, 2022 ​ 114 ​ ​ 1.74 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ February 14, 2022 ​ 113 ​ ​ 1.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.29 ​ ​ 0.30 ​ 0 ​ February 21, 2022 ​ 113 ​ ​ 1.89 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.37 ​ ​ 0.37 ​ 0 ​ February 25, 2022 ​ 113 ​ ​ 1.91 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ March 30, 2022 ​ 114 ​ ​ 2.43 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ April 1, 2022 ​ 114 ​ ​ 2.53 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.33 ​ ​ 0.34 ​ 0 ​ April 6, 2022 ​ 114 ​ ​ 2.70 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.32 ​ ​ 0.32 ​ 0 ​ April 11, 2022 ​ 114 ​ ​ 2.82 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.30 ​ ​ 0.31 ​ 0 ​ May 2, 2022 ​ 113 ​ ​ 3.03 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.25 ​ 0 ​ May 9, 2022 ​ 113 ​ ​ 3.00 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ May 11, 2022 ​ 113 ​ ​ 2.92 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.20 ​ ​ 0.20 ​ 0 ​ May 16, 2022 ​ 113 ​ ​ 2.86 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.22 ​ ​ 0.23 ​ 0 ​ May 31, 2022 ​ 113 ​ ​ 2.84 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.24 ​ 0 ​ June 1, 2022 ​ 113 ​ ​ 2.96 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.25 ​ 0 ​ June 6, 2022 ​ 113 ​ ​ 3.05 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.26 ​ ​ 0.26 ​ 0 ​ June 13, 2022 ​ 112 ​ ​ 3.55 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ June 17, 2022 ​ 112 ​ ​ 3.02 ​ ​ 1.37 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ June 17, 2022 ​ 112 ​ ​ 3.02 ​ ​ 1.64 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ June 17, 2022 ​ 112 ​ ​ 3.35 ​ ​ 4.27 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ July 1, 2022 ​ 112 ​ ​ 2.90 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ July 1, 2022 ​ 112 ​ ​ 2.90 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ July 1, 2022 ​ 112 ​ ​ 2.90 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ July 5, 2022 ​ 112 ​ ​ 2.85 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.22 ​ ​ 0.22 ​ 0 ​ July 6, 2022 ​ 112 ​ ​ 2.98 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.26 ​ 0 ​ July 25, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.25 ​ 0 ​ August 1, 2022 ​ 112 ​ ​ 2.65 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.28 ​ ​ 0.28 ​ 0 ​ August 1, 2022 ​ 112 ​ ​ 2.65 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.28 ​ ​ 0.28 ​ 0 ​ August 5, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.34 ​ ​ 0.34 ​ 0 ​ August 5, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.34 ​ ​ 0.34 ​ 0 ​ August 5, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.34 ​ ​ 0.34 ​ 0 ​ August 5, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.34 ​ ​ 0.34 ​ 0 ​ August 8, 2022 ​ 112 ​ ​ 2.88 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.38 ​ ​ 0.39 ​ 0 ​ August 17, 2022 ​ 112 ​ ​ 3.02 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.30 ​ ​ 0.31 ​ 0 ​ August 19, 2022 ​ 113 ​ ​ 3.09 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.27 ​ ​ 0.27 ​ 0 ​ August 22, 2022 ​ 113 ​ ​ 3.15 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.27 ​ ​ 0.27 ​ 0 ​ August 22, 2022 ​ 113 ​ ​ 3.15 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.27 ​ ​ 0.27 ​ 0 ​ August 29, 2022 ​ 113 ​ ​ 3.24 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.26 ​ ​ 0.27 ​ 0 ​ August 29, 2022 ​ 113 ​ ​ 3.24 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.26 ​ ​ 0.27 ​ 0 ​ August 31, 2022 ​ 113 ​ ​ 3.28 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.25 ​ 0 ​ September 21, 2022 ​ 113 ​ ​ 3.70 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.23 ​ 0 ​ September 23, 2022 ​ 113 ​ ​ 3.91 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Grant Date Volatility ​ Risk-Free Interest Rate ​ Expected Life (In Years) ​ Dividend Yield ​ ​ ​ Common Share Price ​ ​ Strike Price Forfeiture Rate ​ September 23, 2022 ​ 113 ​ ​ 3.91 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ September 26, 2022 ​ 113 ​ ​ 4.11 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.22 ​ ​ 0.22 ​ 0 ​ September 26, 2022 ​ 113 ​ ​ 4.11 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.22 ​ ​ 0.22 ​ 0 ​ October 4, 2022 ​ 112 ​ ​ 3.96 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.22 ​ 0 ​ November 3, 2022 ​ 112 ​ ​ 4.31 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.23 ​ 0 ​ November 7, 2022 ​ 112 ​ ​ 4.35 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.24 ​ 0 ​ November 8, 2022 ​ 112 ​ ​ 4.27 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ November 9, 2022 ​ 112 ​ ​ 4.24 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.23 ​ 0 ​ November 14, 2022 ​ 111 ​ ​ 3.98 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.24 ​ 0 ​ November 21, 2022 ​ 111 ​ ​ 3.96 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ December 1, 2022 ​ 111 ​ ​ 3.65 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.20 ​ ​ 0.21 ​ 0 ​ December 9, 2022 ​ 111 ​ ​ 3.72 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.19 ​ ​ 0.19 ​ 0 ​ ​ For the years ended December 31, 2022 and 2021, the Company recorded $7,891 and $7,092 of stock-based expense. ​

Warrants

Warrants	12 Months Ended
	Dec. 31, 2022
Warrants
Warrants	15. Warrants The Company values warrants issued in equity placements using the Black Scholes model to allocate the fair value of the proceeds from equity financings using a relative fair value approach. Like other stock-based compensation, management uses judgment to determine the inputs to the Black-Scholes option pricing model including the expected life, and underlying share price volatility. Changes in these assumptions will impact the calculation of fair value and the value attributed to the warrants. The Company calculates volatility of warrants based on the historical price of the Company’s stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. In connection with the July 1, 2022 asset acquisition of Revo Squared, the Company issued a ten-year warrant to purchase 10,000,000 common shares at a per share exercise price equal to $0.2201. The warrants may be exercised on a cash or cashless basis, at the election of the warrant holder. As of December 31, 2022, no warrants have been exercised. In connection with the July 15, 2022 asset acquisition of Assisi, the Company issued a ten-year warrant to purchase 22,000,000 common shares at a per share exercise price equal to $0.2520. The warrants may be exercised on a cash or cashless basis, at the election of the warrant holder. As of December 31, 2022, no warrants have been exercised. As of December 31, 2022, details of the outstanding warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Average ​ ​ Exercise ​ Warrants ​ Remaining Original Issue date ​ Price ​ Outstanding ​ Life February 14, 2020 (Series A) ​ 0.1500 ​ 197,917 ​ 2.12 April 9, 2020 (Series B) ​ 0.1500 ​ 363,501 ​ 2.27 May 29, 2020 (Series C) ​ 0.1500 ​ - ​ - July 7, 2020 (Series D) ​ 0.1600 ​ - ​ - July 1, 2022 (Revo Squared) ​ 0.2201 ​ 10,000,000 ​ 9.51 July 15, 2022 (Assisi) ​ 0.2520 ​ 22,000,000 ​ 9.55 Balance at December 31, 2022 32,561,418 ​ Cumulative warrants exercised and expired as of December 31, 2022 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants ​ Warrants ​ Warrant Series ​ Exercised ​ ​ Amount ​ Expired ​ ​ Amount ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Series A 21,677,084 ​ $ 4,293 — ​ $ — Series B 17,969,833 ​ 2,695 — ​ — Series C 133,213,333 ​ 19,982 120,000 ​ 18 Series D 187,269,000 ​ 29,963 231,000 ​ 37 Total 360,129,250 ​ $ 56,933 351,000 ​ $ 55 ​

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes
Income Taxes	16. Income Taxes The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 23% to the effective tax rate is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 ​ 2021 Loss before income taxes ​ $ (19,381) ​ $ (20,717) Expected income tax expense (benefit) ​ (4,458) ​ ​ (4,765) Difference in foreign tax rates ​ 235 ​ ​ 180 Tax rate changes and other adjustments ​ (5) ​ ​ 49 Changes in stock based compensation ​ (1,177) ​ ​ — Foreign accrual property income ​ 9 ​ ​ 16 Stock based compensation and nondeductible expenses ​ 241 ​ ​ 1,394 Prior period adjustment ​ — ​ ​ 162 Share issuance costs recorded in equity ​ — ​ ​ (3,285) Section 382 derecognition ​ — ​ ​ 4,344 Change in valuation allowance ​ 2,789 ​ ​ (428) Total deferred income tax benefit ​ $ (2,366) ​ $ (2,333) ​ The following table summarizes the components of deferred tax: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 Deferred tax assets ​ ​ ​ ​ ​ ​ Intangible assets - licenses ​ $ 4,236 ​ $ 4,236 Share issuance costs ​ 2,482 ​ 3,425 Reserves ​ 478 ​ 181 Non-capital loss carried forward - Canada ​ 10,668 ​ 8,387 Net operating losses carried forward - US ​ 2,885 ​ 2,592 Investment tax credits ​ 208 ​ 30 Operating leases ​ 2 ​ 4 Stock-based compensation ​ 3,067 ​ — Other ​ 478 ​ — Total deferred tax assets ​ $ 24,504 ​ $ 18,855 ​ ​ ​ ​ ​ ​ ​ Deferred tax liabilities ​ ​ Property and equipment ​ (491) ​ (139) Intangibles ​ (6,271) ​ (6,079) Other ​ — ​ (148) Total deferred tax liabilities ​ $ (6,762) ​ $ (6,366) ​ ​ ​ ​ ​ ​ ​ Valuation allowance ​ 18,987 ​ 16,198 Net deferred tax liability ​ $ (1,245) ​ $ (3,709) ​ No deferred tax asset has been recognized for Canada, as it is not more likely than not to be realized. Consequently, a valuation allowance has been applied against the net deferred tax asset. The Canadian non-capital loss carry forwards expire as noted in the table below. ​ ​ ​ ​ ​ ​ ​ 2036 $ 3,763 ​ 2037 ​ ​ 4,279 ​ 2038 ​ ​ 5,417 ​ 2039 ​ ​ 6,774 ​ 2040 ​ ​ 7,418 ​ 2041 ​ ​ 9,629 ​ 2042 ​ ​ 9,104 Total ​ $ 46,384 ​ The Company’s US federal net-operating income tax losses expire as follows: ​ ​ ​ ​ ​ ​ ​ 2035 $ 856 ​ 2036 ​ ​ 1,485 ​ 2037 ​ ​ 3,832 ​ Indefinitely (subject to 80% limitation) ​ ​ 26,283 ​ Derecognized under Section 382 ​ ​ (21,013) Total ​ ​ $ 11,443 ​ As of December 31, 2022, we had net operating loss carryforwards for U.S. federal and state income tax purposes of $32,456 and noncapital loss carryforwards for Canada of $46,384, which will begin to expire in fiscal year 2035. We have evaluated the factors bearing upon the realizability of our deferred tax assets, which are comprised principally of net operating loss carryforwards and noncapital loss carryforwards. In 2021, we concluded that, due to the limitations under Section 382, our U.S. federal and state income tax net operating loss carryforwards, as well as R&D credit carryforwards, for the periods prior to February 11, 2021 have been limited to zero. We therefore have derecognized $21,013 of this asset, reducing the carryforward of these amounts to $11,443. In prior years, there were no uncertain tax positions. In connection with the acquisition of PulseVet, as part of the BPA transaction completed in 2021, it was assessed that an uncertain tax position exists related to withholding taxes on royalties for approximately $265. An uncertain tax liability and an indemnification asset were recorded. It is the Company's policy to record interest within interest expense and penalties in non-operating income. Tax years subject to examination for US federal and state jurisdictions are generally years from 2019 and forward. Tax years subject to examination in Canada are from years 2018 and forward. The Company is in an overall net deferred tax liability position for the year ended December 31, 2022. Management has assessed that the future taxable income resulting from the deferred tax liability position will result in partial utilization of the company's US federal and state net operating loss carryforwards and has therefore concluded a valuation allowance of $1,600 is currently necessary. Due to the uncertainty of realizing any tax benefits as of December 31, 2022 due to historical losses, a full valuation allowance remains necessary to fully offset our Canadian deferred tax assets.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies
Commitments and Contingencies	17. Commitments and Contingencies On May 10, 2018, the Company entered into a Development, Commercialization and Exclusive Distribution Agreement. As part of the agreement, the Company is required to make the following future milestone payments: ● 1st payment: $3,500 in cash payment upon the achievement of future development milestones ● 2nd payment: $3,500 in equity, determined by dividing the amount due by the volume-weighted average price of the Company’s common stock on the NYSE American exchange over the 10 trading days prior to the achievement of the milestone event. As of December 31, 2022, none of the future development milestones related to the above agreement have been met. The Company has assessed the probability of meeting the above milestones and has determined that an accrual is not necessary as of December 31, 2022, and December 31, 2021. From time to time, the Company may be exposed to claims and legal actions in the normal course of business. As of December 31, 2022, and continuing as of March 15, 2023, the Company is not aware of any pending or threatened material litigation claims against the Company.

Segmented Information

Segmented Information	12 Months Ended
	Dec. 31, 2022
Segmented Information
Segmented Information	18. Segmented Information The Company’s operations are comprised of two reportable segments: ● Diagnostics, which consists of TRUFORMA ® products, and ● Therapeutics, which consists of PulseVet ® and Assisi ® products The Company’s Chief Operating Decision Maker (CODM) is its Chief Executive Officer who has ultimate responsibility for enterprise decisions. Although our reportable segments provide similar products, each one is managed separately to better align with the Company’s customers and distribution / development partners. The CODM determines resource allocation for, and monitors performance of, the consolidated enterprise, the Diagnostics segment, and the Therapeutics segment together. The CODM relies on internal segment reporting that analyzes results on certain key performance indicators, namely, revenues and gross profit. Costs below gross profit are not allocated to the segments. The following is a reconciliation of consolidated revenue, cost of revenue, and gross profit amongst our reportable segments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diagnostics Therapeutics Consolidated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenue ​ $ 391 ​ $ 18,539 ​ $ 18,930 Cost of revenue ​ 265 ​ 5,013 ​ 5,278 Gross profit ​ $ 126 ​ $ 13,526 ​ $ 13,652 ​

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2022
Loss Per Share
Loss Per Share	19. Loss Per Share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ December 31, ​ ​ 2022 ​ ​ 2021 Numerator ​ ​ ​ Net loss for the period $ (17,015) ​ $ (18,384) Charge to retained earnings for preferred share exchange — ​ (32,039) Loss attributable to common shareholders ​ (17,015) ​ ​ (50,423) ​ ​ ​ ​ ​ ​ Denominator ​ ​ ​ ​ Weighted average shares - basic 979,924,052 ​ 956,533,761 Stock options — ​ — Warrants — ​ — Denominator for diluted loss per share 979,924,052 ​ 956,533,761 ​ ​ ​ ​ ​ ​ Loss per share - basic and diluted $ (0.02) ​ $ (0.05) ​ As of December 31, 2022, and 2021, the Company had stock options outstanding of 84,112,443 and 50,717,724 and warrants outstanding of 32,561,418 and 912,418. These securities could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would be anti-dilutive.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events
Subsequent Events	20. Subsequent Events Agreement with Structured Medical Products to begin commercializing VetGuardian TM On January 13, 2023, Zomedica Inc. entered into a Distribution Agreement with Structured Monitoring Products, Inc. (“SMP”) whereby the Company acquired non-exclusive rights to distribute the VetGuardian remote animal vital sign and surveillance monitoring device. The Distribution Agreement was entered into as a result of the Company exercising its right to commercialize the Product pursuant to a Note Purchase Agreement with an effective date of May 16, 2022 between the Company and SMP. The Company will purchase the Products from SMP for resale and will share service fees with SMP. The Distribution Agreement is for a term of two years with automatic renewals of twelve months unless either party provides written notice of its intent not to renew. The Distribution Agreement contains customary representations, warranties and covenants of the parties. The Distribution Agreement also contains indemnification provisions pursuant to which SMP has agreed to indemnify the Company and its affiliate against certain losses, subject to the limitations set forth therein. Agreement with Qorvo to take over new assay development and manufacturing of TRUFORMA product line through long-term agreement with Qorvo Biotechnologies, LLC On January 17, 2023, Zomedica Corp., along with its U.S. subsidiary Zomedica Inc. ("ZomInc," and together with the Company, the "Zomedica Entities"), entered into three related agreements with Qorvo Biotechnologies, LLC ("Qorvo"). These agreements include a Transition and Support Agreement, a BAW Sensor Supply Agreement, and a Development and Manufacturing License Agreement. ​ The Qorvo Agreements represent a strategic restructuring of the Zomedica Entities' prior development and commercialization agreement with Qorvo for the Company's TRUFORMA ® line of products. Under the Qorvo Agreements, ZomInc will take control of aspects of the TRUFORMA product line previously provided by Qorvo, including development of new assays and manufacturing both instruments and assay cartridges. This will position the Zomedica Entities to invest in accelerated development of new TRUFORMA assays and to begin manufacturing directly. ZomInc will provide up-front licensing and certain milestone payments, and an option payment if ZomInc exercises its option to extend exclusive rights for TRUFORMA in the veterinary health market in perpetuity. A related agreement provides ZomInc the right to purchase Bulk Acoustic Wave sensors from Qorvo for inclusion in the TRUFORMA products. ​ While Qorvo will continue to work with ZomInc to develop the TRUFORMA assays currently planned, including the first assay for the equine market and several assays for non-infectious gastrointestinal disease, Qorvo has agreed to provide technology transfer assistance to ZomInc to undertake all future new assay development for the TRUFORMA product line. Qorvo has also agreed to assist ZomInc to install manufacturing capabilities at the Zomedica Entities' Global Manufacturing and Distribution Center in Roswell, Georgia. The Zomedica Entities will thereafter have control of development, manufacturing, and commercialization of the TRUFORMA product line. The Zomedica Entities expect the manufacturing transfer process to take up to 18 months as specialized manufacturing equipment is produced and installed at the Roswell facility.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Basis of Measurement	Basis of Measurement The consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.
Business Combinations	Business Combinations We account for business combinations in accordance with ASC 805, Business Combinations, if the acquired assets assumed and liabilities incurred constitute a business. We consider acquired companies to constitute a business if the acquired net assets and processes have the ability to create outputs in the form of revenue. For acquired companies constituting a business, we recognize the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognize any excess of total consideration paid over the fair value of the identifiable net assets as goodwill.
Estimates and Assumptions	Estimates and Assumptions In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Functional and Reporting Currencies	Functional and Reporting Currencies The functional currency, as determined by management, for our subsidiaries in the United States, Switzerland, and Canada is U.S. dollars, which is also our reporting currency. The functional currency, as determined by management, for our Japanese subsidiary is Japanese Yen. Japanese Yen are translated for financial reporting purposes with translation gains and losses recorded as a component of other comprehensive income or loss. In respect of transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are measured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these transactions are recognized in the consolidated statements of operations and comprehensive loss.
Comparative Figures	Comparative Figures Construction in progress is separately stated in the current period balance sheet for $692 . The consolidated balance sheets for the year ended December 31, 2021 have been adjusted for $420 of construction in progress that was included in intangible assets and property and equipment. This amount has been reclassified to a separate line in the balance sheet to conform to the current year presentation. The change in presentation had no effect on the reported results of operations. These changes in classification do not affect previously reported cash flows from operating activities in the consolidated statements of cash flows.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets held. The Company adopted ASU 2016-13 as of January 1, 2022 and there was no significant impact on its consolidated condensed financial statements and related disclosures as a result. The Company considered, among other things, historical trends and projected economic / market conditions and determined that the estimate of credit losses was not significantly impacted.
Segment Reporting	Segment Reporting The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company’s reportable segments, reporting of which began in 2021, consist of Diagnostics and Therapeutics.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid securities with an original maturity of three months or less to be cash equivalents.
Investment Securities	Investment Securities Our investment securities, which are comprised of corporate bonds/notes and US treasuries, are accounted for in accordance with ASC 320, “Investments – Debt and Equity Securities” (“ASC 320”). The company considers all of its securities for which there is a determinable fair market value, and there are no restrictions on the Company’s ability to sell within the next 12 months, as available for sale. We classify these securities as both current and non-current depending on their time to maturity. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported as a component of shareholders’ equity.
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses Accounts receivables are recorded net of an allowance for credit losses and have payment terms of 30 days. Our policy for determining the allowance is based on factors that affect collectability, including: (a) historical trends of write-offs, recoveries, and credit losses; (b) the credit quality of our customers; and (c) projected economic and market conditions. As of December 31, 2022, our allowance was $71 and was recorded net in trade receivables. While we believe that our allowance for credit losses is adequate and represents our best estimate as of December 31, 2022, we continue to closely monitor customer liquidity and industry and economic conditions, which may result in changes to these estimates.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. The Company utilizes the specific identification and First in, First out ("FIFO") method to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
Property and Equipment	Property and Equipment Property and equipment are carried at historical cost less accumulated depreciation and any accumulated impairment losses. Property and equipment acquired in a business combination are recorded at fair value as of the date of acquisition. Maintenance and repair expenditures that do not improve or extend the life are expensed in the period incurred. Depreciation is recognized so as to write off the cost less their residual values over their useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss. During the quarter ended September 30, 2022, the company changed its policy of recognizing TRUFORMA ® instruments as inventory and reclassified $3,364 to property and equipment, depreciable over 10 years , where they are to remain undepreciated until they are placed with customers. As of the year ended December 31, 2022, the balance related to these undepreciated instruments in property and equipment is $3,487 . Estimated useful lives for the principal asset categories are as follows: ​ ​ ​ ​ Office equipment 3 years Furniture and equipment 5 - 7 years Laboratory equipment 5 - 7 years Machinery and equipment 5 - 10 years Leasehold improvements Over shorter of estimated useful life and lease term ​
Intangible assets	Intangible Assets Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life. Costs related to acquired trademarks, tradename, customer relationships and developed technology have been capitalized and amortized over the estimated useful life. Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives and amortization methods are reviewed at the end of each year, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses. ​ ​ ​ ​ ​ E-commerce technology 2 years Computer software and website 3 years Tradename 5 - 19 years Developed technology 10 - 15 years Customer relationships 11 - 19 years Trademarks 15 years ​
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the sum of estimated undiscounted future cash flows associated with the asset or group of assets is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.
Share Issue Costs	Share Issue Costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock.
Revenue Recognition	Revenue Recognition The Company enters into agreements which may contain multiple promises where customers purchase products, services, or a combination thereof. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires judgment. We determine the transaction price for a contract based on the total consideration we expect to receive in exchange for the transferred goods or services. The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company's contracts with customers are generally comprised of purchase orders for the sale of the point of care instrument, consumable products, and extended warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The extended warranties are also a separate performance obligation, whereby revenue is recognized over time. The nature of the Company’s PulseVet business gives rise to variable consideration, including discounts and applicator (“trode”) returns for refurbishment. Credits are issued for unused shocks on returned trodes, which can be used toward the purchase of replacement trodes. Discounts and the estimated unused shock credits decrease the transaction price, which reduces revenue. Variable consideration related to unused shock credits is estimated using the expected value method, which estimates the amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration are based upon historical experience and known trends. These estimated credits are nonrefundable and may only be used towards the purchase of future trode refurbishments. This practice encourages refurbishment purchase prior to complete utilization of the previous trode, so the customer will always have a trode on hand with ample capacity to perform treatments. At times the Company receives consideration prior to when the performance obligation is completed, giving rise to a contract liability. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority. Disaggregated revenue for the years ended December 31, 2022 and 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diagnostics ​ ​ Therapeutics ​ ​ ​ 2022 ​ ​ 2021 ​ ​ 2022 ​ ​ 2021 Consumables ​ $ 391 ​ $ 125 ​ $ 2,072 ​ $ - Instruments ​ ​ - ​ ​ - ​ ​ 7,269 ​ ​ 1,793 Trodes ​ ​ - ​ ​ - ​ ​ 8,681 ​ ​ 2,073 Other (e.g., Warranty and Repairs) ​ ​ - ​ ​ - ​ ​ 517 ​ ​ 142 Total revenue ​ $ 391 ​ $ 125 ​ $ 18,539 ​ $ 4,008
Cost of Revenue	Cost of goods sold consists of materials, labor, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of revenue.
Research and Development	Research and Development Research and development costs related to continued research and development programs are expensed as incurred.
Stock-based Compensation	Stock-based Compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of the Company’s stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, on a tax jurisdictional basis. The Company files income tax returns in Canada and the province of Alberta and its subsidiaries file income tax returns in the United States and various states, including in Michigan where the Company’s headquarters are located. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized. The Company assesses the likelihood of the financial statement effect of an uncertain tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in jurisdictions such as the United States and Canada. The Company recognizes tax-related interest and penalties, if any, as a component separate from income tax expense .
Comprehensive Loss	Comprehensive Loss The Company follows ASC topic 220. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders’ equity. The Company has recorded a currency translation adjustment associated with its Japanese subsidiary.
Loss Per Share	Loss Per Share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options is excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during fiscal 2022 and 2021 were not included in the computation of diluted EPS because the Company has incurred a loss for the years ended December 31, 2022 and 2021 and the effect would be anti-dilutive.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Estimated useful lives of property, plant and equipment	​ ​ ​ ​ Office equipment 3 years Furniture and equipment 5 - 7 years Laboratory equipment 5 - 7 years Machinery and equipment 5 - 10 years Leasehold improvements Over shorter of estimated useful life and lease term ​
Estimated lives of finite-lived intangible assets	​ ​ ​ ​ ​ E-commerce technology 2 years Computer software and website 3 years Tradename 5 - 19 years Developed technology 10 - 15 years Customer relationships 11 - 19 years Trademarks 15 years ​
Schedule of segmented revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diagnostics ​ ​ Therapeutics ​ ​ ​ 2022 ​ ​ 2021 ​ ​ 2022 ​ ​ 2021 Consumables ​ $ 391 ​ $ 125 ​ $ 2,072 ​ $ - Instruments ​ ​ - ​ ​ - ​ ​ 7,269 ​ ​ 1,793 Trodes ​ ​ - ​ ​ - ​ ​ 8,681 ​ ​ 2,073 Other (e.g., Warranty and Repairs) ​ ​ - ​ ​ - ​ ​ 517 ​ ​ 142 Total revenue ​ $ 391 ​ $ 125 ​ $ 18,539 ​ $ 4,008

Investment securities (Tables)

Investment securities (Tables)	12 Months Ended
	Dec. 31, 2022
Investment Securities
Schedule of company's investment securities	The following represents the Company’s investment securities as of December 31, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition Cost ​ ​ Accretion / (Amortization) ​ ​ Unrealized Gain / (Loss) ​ ​ Estimated Fair Value Commercial paper ​ $ 30,634 ​ $ 471 ​ $ (139) ​ $ 30,966 Corporate notes / bonds ​ ​ 44,115 ​ ​ 192 ​ ​ (547) ​ ​ 43,760 Debt security ​ ​ 1,000 ​ ​ - ​ ​ - ​ ​ 1,000 Money market funds ​ ​ 10,196 ​ ​ - ​ ​ - ​ ​ 10,196 U.S. govt. agencies ​ ​ 46,223 ​ ​ 85 ​ ​ (230) ​ ​ 46,078 U.S. treasuries ​ ​ 15,629 ​ ​ 99 ​ ​ (145) ​ ​ 15,583 Total investment securities ​ $ 147,797 ​ $ 847 ​ $ (1,061) ​ $ 147,583
Schedule of contractual maturities of investment securities	Contractual maturities of investment securities as of December 31, 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition Cost ​ ​ Estimated Fair Value Original maturities of 90 days or less ​ $ 19,127 ​ $ 19,178 Original maturities of 91-365 days ​ ​ 87,528 ​ ​ 87,693 Original maturities of 366+ days ​ ​ 41,142 ​ ​ 40,712 Total investment securities ​ $ 147,797 ​ $ 147,583

Fair value measurements (Tables

Fair value measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Measurements
Schedule of the fair value of our investments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 ​ ​ Level 2 ​ ​ Level 3 ​ ​ Estimated Fair Value Commercial paper ​ $ - ​ $ 30,966 ​ $ - ​ $ 30,966 Corporate notes / bonds ​ ​ - ​ ​ 43,760 ​ ​ - ​ ​ 43,760 Debt security ​ ​ - ​ ​ - ​ ​ 1,000 ​ ​ 1,000 Money market funds ​ ​ 10,196 ​ ​ - ​ ​ - ​ ​ 10,196 U.S. govt. agencies ​ ​ 46,078 ​ ​ - ​ ​ - ​ ​ 46,078 U.S. treasuries ​ ​ 15,583 ​ ​ - ​ ​ ​ ​ ​ 15,583 Total investment securities ​ $ 71,857 ​ $ 74,726 ​ $ 1,000 ​ $ 147,583
Schedule of investments and balance sheet classifications	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash & Cash Equiv. ​ ​ Available- For-Sale (Current) ​ ​ Available- For-Sale (Non-Current) ​ ​ Estimated Fair Value Commercial paper ​ $ - ​ $ 30,966 ​ $ - ​ $ 30,966 Corporate notes / bonds ​ ​ - ​ ​ 24,272 ​ ​ 19,488 ​ ​ 43,760 Debt security ​ ​ - ​ ​ - ​ ​ 1,000 ​ ​ 1,000 Money market funds ​ ​ 10,196 ​ ​ - ​ ​ - ​ ​ 10,196 U.S. govt. agencies ​ ​ 8,982 ​ ​ 23,597 ​ ​ 13,499 ​ ​ 46,078 U.S. treasuries ​ ​ - ​ ​ 8,858 ​ ​ 6,725 ​ ​ 15,583 Total investment securities ​ $ 19,178 ​ $ 87,693 ​ $ 40,712 ​ $ 147,583

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2022
Assisi
Summary of acquisition date fair values	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial Measurement ​ ​ ​ ​ Allocation of ​ Period ​ Updated ​ Consideration Adjustments Allocation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Inventory, net ​ $ 220 ​ $ — ​ $ 220 Prepaid expenses and deposits ​ 271 ​ — ​ 271 Other receivables ​ ​ 406 ​ ​ (206) ​ ​ 200 Right of use asset ​ ​ — ​ ​ 260 ​ ​ 260 Intangible Assets (estimated useful life) ​ ​ ​ ​ ​ ​ ​ ​ E-commerce technology ( 2 years) ​ 200 ​ — ​ 200 Trade name ( 5 years) ​ 300 ​ — ​ 300 Developed technology ( 10 years) ​ 4,500 ​ — ​ 4,500 Customer relationships ( 19 years) ​ 2,800 ​ — ​ 2,800 Total assets acquired ​ 8,697 ​ 54 ​ 8,751 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current portion of lease obligations ​ ​ — ​ 49 ​ 49 Non current portion of lease obligations ​ ​ — ​ 211 ​ 211 Other non current liabilities ​ ​ 45 ​ — ​ 45 Total liabilities assumed ​ 45 ​ 260 ​ 305 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired, excluding goodwill ​ 8,652 ​ (206) ​ 8,446 Goodwill ​ 14,329 ​ 206 ​ 14,535 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired ​ $ 22,981 ​ $ — ​ $ 22,981 ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2022 ​ 2021 Net Revenue $ 21,838 ​ $ 8,841 Net Losses $ (18,038) ​ $ (18,822) ​
Summary of purchase price consideration	​ ​ ​ ​ ​ Cash ​ $ 18,293 Fair value of warrants ​ $ 4,688 Total ​ $ 22,981
Schedule of pro forma financial information	​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2022 ​ 2021 Adjustments to net revenues ​ ​ ​ ​ ​ Assisi preacquisition revenues $ 2,908 ​ $ 4,708 Adjustments to net income ​ ​ ​ ​ ​ Assisi preacquisition net losses $ (639) ​ $ (438)
Revo Squared
Summary of acquisition date fair values	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial Measurement ​ ​ ​ ​ Allocation of ​ Period ​ Updated ​ Consideration Adjustments Allocation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade receivables, net ​ $ 8 ​ $ — ​ $ 8 Prepaid expenses and deposits ​ 10 ​ — ​ 10 Intangible Assets (estimated useful life) ​ ​ ​ ​ ​ ​ ​ ​ Trade name ( 5 years) ​ 200 ​ — ​ 200 Developed technology ( 10 years) ​ 2,300 ​ — ​ 2,300 Customer relationships ( 16 years) ​ 1,200 ​ — ​ 1,200 Total assets acquired ​ 3,718 ​ — ​ 3,718 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnout liabilities ​ 2,458 ​ (458) ​ 2,000 Total liabilities assumed ​ 2,458 ​ (458) ​ 2,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired, excluding goodwill ​ 1,260 ​ 458 ​ 1,718 Goodwill ​ 6,528 ​ (458) ​ 6,070 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired ​ $ 7,788 ​ $ — ​ $ 7,788
Summary of purchase price consideration	​ ​ ​ ​ ​ Cash ​ $ 6,011 Fair value of warrants ​ $ 1,777 Total ​ $ 7,788
PulseVet
Summary of acquisition date fair values	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial Measurement ​ ​ ​ ​ Allocation of ​ Period ​ Updated ​ Consideration Adjustments Allocation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 526 ​ $ 3 ​ $ 529 Trade receivables ​ 269 ​ — ​ 269 Inventory ​ 840 ​ 31 ​ 871 Prepaid expenses and deposits ​ 365 ​ — ​ 365 Other receivables ​ — ​ 150 ​ 150 Property and equipment ​ 125 ​ — ​ 125 Intangible Assets (estimated useful life) ​ ​ ​ ​ ​ ​ ​ ​ Customer relationships ( 11 years) ​ 22,650 ​ — ​ 22,650 Developed technology ( 15 years) ​ 8,650 ​ — ​ 8,650 Trade name ( 19 years) ​ 2,350 ​ — ​ 2,350 Other Assets ​ 69 ​ 265 ​ 334 Total assets acquired ​ 35,844 ​ 449 ​ 36,293 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts payable and accrued liabilities ​ 1,112 ​ (543) ​ 569 Income tax payable ​ 44 ​ — ​ 44 Deferred revenue ​ 61 ​ — ​ 61 Liability for contracts with customers ​ 332 ​ — ​ 332 Deferred tax liabilities ​ 7,138 ​ (814) ​ 6,324 Other non current liabilities ​ 143 ​ 265 ​ 408 Total liabilities assumed ​ 8,830 ​ (1,092) ​ 7,738 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired, excluding goodwill ​ 27,014 ​ 1,541 ​ 28,555 Goodwill ​ 44,915 ​ (1,541) ​ 43,374 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net assets acquired ​ $ 71,929 ​ $ — ​ $ 71,929

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory
Summary of inventory	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ December 31, 2021 ​ ​ Diagnostics Therapeutics Consolidated Diagnostics Therapeutics Consolidated Raw Materials ​ $ — ​ $ 1,685 ​ $ 1,685 ​ $ — ​ $ 890 ​ $ 890 Finished Goods ​ — ​ 182 ​ 182 ​ — ​ 140 ​ 140 Purchased Inventory ​ 919 ​ — ​ 919 ​ 1,848 ​ — ​ 1,848 Total ​ 919 ​ 1,867 ​ 2,786 ​ 1,848 ​ 1,030 ​ 2,878 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Reserves ​ (18) ​ (22) ​ (40) ​ (9) ​ (21) ​ (30) Net inventory ​ $ 901 ​ $ 1,845 ​ $ 2,746 ​ $ 1,839 ​ $ 1,009 ​ $ 2,848

Prepaid Expenses and Deposits (

Prepaid Expenses and Deposits (Tables)	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses and Deposits.
Schedule of prepaid expenses and deposits	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 Deposits ​ $ 1,886 ​ $ 1,340 Prepaid marketing ​ 114 ​ 83 Prepaid insurance ​ 614 ​ 599 Prepaid taxes ​ 753 ​ — Other ​ 620 ​ 214 Total prepaid expenses and deposits ​ $ 3,987 ​ $ 2,236

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property and Equipment
Schedule of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ Machinery and office equipment ​ $ 6,487 ​ $ 1,392 Furniture and equipment ​ 111 ​ 110 Laboratory equipment ​ 249 ​ 225 Leasehold improvements ​ 1,239 ​ 287 ​ ​ 8,086 ​ 2,014 ​ ​ ​ ​ ​ ​ ​ Accumulated depreciation and amortization ​ 1,277 ​ 884 Net property and equipment ​ $ 6,809 ​ $ 1,130 ​

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible Assets
Schedule of Finite-Lived Intangible Assets	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ Computer software ​ $ 350 ​ $ 28 Customer relationships ​ 26,651 ​ 22,650 Technology ​ 15,650 ​ 8,650 Trademarks ​ 16 ​ 16 Tradename ​ 2,850 ​ 2,350 Website ​ 962 ​ 546 ​ ​ 46,479 ​ 34,240 ​ ​ ​ ​ ​ ​ ​ Accumulated amortization ​ 4,680 ​ 1,064 Net intangibles ​ $ 41,799 ​ $ 33,176 ​
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated future amortization of intangible assets is as follows: ​ ​ ​ ​ 2023 $ 4,098 2024 ​ 4,067 2025 ​ 3,903 2026 ​ 3,781 2027 and beyond ​ 25,950 Total ​ $ 41,799 ​

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases
Lessee, Operating Lease, Right of Use Asset and Lease Liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ 2022 ​ 2021 Right-of-use asset ​ Cost ​ ​ Aggregate lease commitments ​ $ 2,759 ​ $ 1,779 Less: impact of present value ​ (262) ​ ​ (155) Balance ​ $ 2,497 ​ $ 1,624 ​ ​ ​ ​ ​ ​ ​ Reduction in right-of-use asset ​ ​ ​ Straight line amortization ​ 946 ​ ​ 346 Interest ​ (114) ​ ​ (42) Balance ​ $ 832 ​ $ 304 ​ ​ ​ ​ ​ ​ ​ Net book value as at: ​ ​ ​ ​ ​ ​ Balance ​ $ 1,665 ​ $ 1,320 ​ ​ ​ ​ ​ ​ ​ Lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additions ​ $ 2,520 ​ $ 1,647 Payments ​ (896) ​ ​ (310) Interest ​ 114 ​ ​ 42 Total lease liabilities ​ $ 1,738 ​ $ 1,379 ​ ​ ​ ​ ​ ​ ​ Current portion of lease liabilities ​ 641 ​ ​ 415 Long term portion of lease liabilities ​ 1,097 ​ ​ 964 Total lease liabilities ​ $ 1,738 ​ $ 1,379 ​
Lessee, Operating Lease, Liability, Maturity	​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ 706 2024 ​ 679 2025 ​ 237 2026 ​ ​ 197 2027 ​ ​ 44 Total lease payments ​ $ 1,863 Less imputed interest ​ ​ 125 Total ​ $ 1,738 ​
Weighted-Average Remaining Lease Term and Discount Rate	​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2022 Weighted-average remaining lease term ​ ​ 2.9 years Weighted-average discount rate ​ ​ 4.5%

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Stock-Based Compensation
Share-based payment arrangement, option, activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Weighted Avg ​ ​ ​ Options ​ Exercise Price ​ Balance at December 31, 2021 50,717,724 $ 0.4466 Stock options granted 47,292,219 ​ ​ 0.2692 ​ Stock options forfeited 4,300,000 ​ ​ 0.6108 ​ Vested stock options expired 9,597,500 ​ ​ 0.2601 ​ Balance at December 31, 2022 84,112,443 ​ $ 0.3602 ​ Vested at December 31, 2022 23,850,099 ​ $ 0.3698 ​ ​
Summary of issued and outstanding stock options	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Avg ​ ​ ​ ​ Number of Options ​ Number of ​ Unvested ​ Remaining Life ​ ​ ​ ​ Issued ​ Vested Options ​ Options ​ Outstanding Grant Date ​ Exercise Price ​ and Outstanding ​ Outstanding ​ Outstanding ​ (Years) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 14, 2020 0.19 1,133,557 837,182 296,375 2.20 July 9, 2020 0.18 175,000 131,250 43,750 2.52 August 25, 2020 0.13 20,000 10,000 10,000 2.65 October 1, 2020 0.11 266,667 191,667 75,000 2.75 October 20, 2020 0.09 20,000 15,000 5,000 2.81 December 31, 2020 0.23 15,742,500 13,002,500 2,740,000 3.00 February 26, 2021 1.87 100,000 100,000 — 3.16 March 1, 2021 2.06 200,000 100,000 100,000 3.17 March 8, 2021 1.88 100,000 100,000 — 3.19 March 15, 2021 2.49 100,000 100,000 — 3.21 May 12, 2021 0.78 3,400,000 1,700,000 1,700,000 3.36 May 14, 2021 0.75 3,200,000 850,000 2,350,000 3.37 August 11, 2021 0.57 525,000 225,000 300,000 3.61 August 18, 2023 0.50 200,000 50,000 150,000 3.63 August 23, 2021 0.50 25,000 25,000 — 3.65 September 13, 2021 0.57 800,000 200,000 600,000 3.70 October 1, 2021 0.58 12,412,500 3,112,500 9,300,000 3.75 January 3, 2022 ​ 0.36 100,000 — 100,000 4.01 January 4, 2022 ​ 0.35 200,000 — 200,000 4.01 January 14, 2022 ​ 0.35 200,000 — 200,000 4.04 January 16, 2022 ​ 0.35 50,000 — 50,000 4.05 January 18, 2022 ​ 0.35 100,000 — 100,000 4.05 February 14, 2022 ​ 0.30 200,000 — 200,000 4.13 February 21, 2022 ​ 0.37 200,000 — 200,000 4.15 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Avg ​ ​ ​ ​ Number of Options ​ Number of ​ Unvested ​ Remaining Life ​ ​ ​ ​ Issued ​ Vested Options ​ Options ​ Outstanding Grant Date ​ Exercise Price ​ and Outstanding ​ Outstanding ​ Outstanding ​ (Years) February 25, 2022 ​ 0.35 12,100,000 — 12,100,000 4.16 March 30, 2022 ​ 0.35 200,000 — 200,000 4.25 April 1, 2022 ​ 0.34 200,000 — 200,000 4.25 April 6, 2022 ​ 0.32 100,000 — 100,000 4.27 April 11, 2022 ​ 0.31 75,000 — 75,000 4.28 May 2, 2022 ​ 0.25 300,000 — 300,000 4.34 May 9, 2022 ​ 0.21 700,000 — 700,000 4.36 May 11, 2022 ​ 0.20 400,000 — 400,000 4.36 May 16, 2022 ​ 0.23 100,000 — 100,000 4.38 May 31, 2022 ​ 0.24 500,000 — 500,000 4.42 June 1, 2022 ​ 0.25 500,000 — 500,000 4.42 June 6, 2022 ​ 0.26 200,000 — 200,000 4.43 June 13, 2022 ​ 0.24 200,000 — 200,000 4.45 June 17, 2022 ​ 0.24 3,100,000 3,100,000 — 4.46 July 1, 2022 ​ 0.21 350,000 — 350,000 4.50 July 5, 2022 ​ 0.22 200,000 — 200,000 4.51 July 6, 2022 ​ 0.26 100,000 — 100,000 4.52 July 25, 2022 ​ 0.25 200,000 — 200,000 4.57 August 1, 2022 ​ 0.28 100,000 — 100,000 4.59 August 5, 2022 ​ 0.34 2,850,000 — 2,850,000 4.60 August 8, 2022 ​ 0.39 100,000 — 100,000 4.61 August 17, 2022 ​ 0.31 200,000 — 200,000 4.63 August 19, 2022 ​ 0.27 200,000 — 200,000 4.64 August 22, 2022 ​ 0.27 400,000 — 400,000 4.64 August 29, 2022 ​ 0.27 400,000 — 400,000 4.66 August 31, 2022 ​ 0.25 800,000 — 800,000 4.67 September 21, 2022 ​ 0.23 200,000 — 200,000 4.73 September 23, 2022 ​ 0.21 400,000 — 400,000 4.73 September 26, 2022 ​ 0.22 300,000 — 300,000 4.74 October 4, 2022 ​ 0.22 4,000,000 — 4,000,000 4.76 November 3, 2022 ​ 0.23 200,000 — 200,000 4.84 November 7, 2022 ​ 0.24 500,000 — 500,000 4.85 November 8, 2022 ​ 0.24 4,950,000 — 4,950,000 4.86 November 9, 2022 ​ 0.23 300,000 — 300,000 4.86 November 14, 2022 ​ 0.24 350,000 — 350,000 4.87 November 21, 2022 ​ 0.21 50,000 — 50,000 4.89 December 1, 2022 ​ 0.21 100,000 — 100,000 4.92 December 9, 2022 ​ 0.19 8,717,219 — 8,717,219 4.94 Balance at December 31, 2022 ​ 84,112,443 23,850,099 60,262,344 ​
Summary of option fair value assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Grant Date Volatility ​ Risk-Free Interest Rate ​ Expected Life (In Years) ​ Dividend Yield ​ ​ ​ Common Share Price ​ ​ Strike Price Forfeiture Rate ​ February 26, 2021 ​ 117 % ​ 0.95 % ​ 10 ​ ​ 0 % ​ $ 1.87 ​ $ 1.87 ​ 0 % March 1, 2021 ​ 117 ​ ​ 0.92 ​ ​ 10 ​ ​ 0 ​ ​ ​ 2.06 ​ ​ 2.06 ​ 0 ​ March 8, 2021 ​ 117 ​ ​ 1.07 ​ ​ 10 ​ ​ 0 ​ ​ ​ 1.88 ​ ​ 1.88 ​ 0 ​ March 15,2021 ​ 117 ​ ​ 1.06 ​ ​ 5.75 ​ ​ 0 ​ ​ ​ 2.49 ​ ​ 2.49 ​ 0 ​ May 12, 2021 ​ 118 ​ ​ 1.11 ​ ​ 6.21 - 6.22 ​ ​ 0 ​ ​ ​ 0.78 ​ ​ 0.78 ​ 0 ​ May 14, 2021 ​ 118 ​ ​ 1.06 ​ ​ 5.75 ​ ​ 0 ​ ​ ​ 0.76 ​ ​ 0.75 ​ 0 ​ May 14, 2021 ​ 118 ​ ​ 1.06 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.75 ​ ​ 0.75 ​ 0 ​ August 11, 2021 ​ 116 ​ ​ 0.96 ​ ​ 6.18 - 6.25 ​ ​ 0 ​ ​ ​ 0.56 ​ ​ 0.57 ​ 0 ​ August 18,2021 ​ 116 ​ ​ 0.93 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.50 ​ ​ 0.50 ​ 0 ​ August 23, 2021 ​ 116 ​ ​ 0.92 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.50 ​ ​ 0.50 ​ 0 ​ October 1, 2021 ​ 116 ​ ​ 1.10 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.57 ​ ​ 0.58 ​ 0 ​ January 3, 2022 ​ 114 ​ ​ 1.50 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.36 ​ ​ 0.36 ​ 0 ​ January 4, 2022 ​ 114 ​ ​ 1.47 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ January 14, 2022 ​ 114 ​ ​ 1.64 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ January 16, 2022 ​ 114 ​ ​ 1.73 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ January 18, 2022 ​ 114 ​ ​ 1.74 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ February 14, 2022 ​ 113 ​ ​ 1.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.29 ​ ​ 0.30 ​ 0 ​ February 21, 2022 ​ 113 ​ ​ 1.89 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.37 ​ ​ 0.37 ​ 0 ​ February 25, 2022 ​ 113 ​ ​ 1.91 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ March 30, 2022 ​ 114 ​ ​ 2.43 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.35 ​ ​ 0.35 ​ 0 ​ April 1, 2022 ​ 114 ​ ​ 2.53 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.33 ​ ​ 0.34 ​ 0 ​ April 6, 2022 ​ 114 ​ ​ 2.70 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.32 ​ ​ 0.32 ​ 0 ​ April 11, 2022 ​ 114 ​ ​ 2.82 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.30 ​ ​ 0.31 ​ 0 ​ May 2, 2022 ​ 113 ​ ​ 3.03 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.25 ​ 0 ​ May 9, 2022 ​ 113 ​ ​ 3.00 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ May 11, 2022 ​ 113 ​ ​ 2.92 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.20 ​ ​ 0.20 ​ 0 ​ May 16, 2022 ​ 113 ​ ​ 2.86 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.22 ​ ​ 0.23 ​ 0 ​ May 31, 2022 ​ 113 ​ ​ 2.84 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.24 ​ 0 ​ June 1, 2022 ​ 113 ​ ​ 2.96 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.25 ​ 0 ​ June 6, 2022 ​ 113 ​ ​ 3.05 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.26 ​ ​ 0.26 ​ 0 ​ June 13, 2022 ​ 112 ​ ​ 3.55 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ June 17, 2022 ​ 112 ​ ​ 3.02 ​ ​ 1.37 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ June 17, 2022 ​ 112 ​ ​ 3.02 ​ ​ 1.64 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ June 17, 2022 ​ 112 ​ ​ 3.35 ​ ​ 4.27 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ July 1, 2022 ​ 112 ​ ​ 2.90 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ July 1, 2022 ​ 112 ​ ​ 2.90 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ July 1, 2022 ​ 112 ​ ​ 2.90 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ July 5, 2022 ​ 112 ​ ​ 2.85 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.22 ​ ​ 0.22 ​ 0 ​ July 6, 2022 ​ 112 ​ ​ 2.98 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.26 ​ 0 ​ July 25, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.25 ​ 0 ​ August 1, 2022 ​ 112 ​ ​ 2.65 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.28 ​ ​ 0.28 ​ 0 ​ August 1, 2022 ​ 112 ​ ​ 2.65 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.28 ​ ​ 0.28 ​ 0 ​ August 5, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.34 ​ ​ 0.34 ​ 0 ​ August 5, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.34 ​ ​ 0.34 ​ 0 ​ August 5, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.34 ​ ​ 0.34 ​ 0 ​ August 5, 2022 ​ 112 ​ ​ 2.94 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.34 ​ ​ 0.34 ​ 0 ​ August 8, 2022 ​ 112 ​ ​ 2.88 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.38 ​ ​ 0.39 ​ 0 ​ August 17, 2022 ​ 112 ​ ​ 3.02 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.30 ​ ​ 0.31 ​ 0 ​ August 19, 2022 ​ 113 ​ ​ 3.09 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.27 ​ ​ 0.27 ​ 0 ​ August 22, 2022 ​ 113 ​ ​ 3.15 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.27 ​ ​ 0.27 ​ 0 ​ August 22, 2022 ​ 113 ​ ​ 3.15 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.27 ​ ​ 0.27 ​ 0 ​ August 29, 2022 ​ 113 ​ ​ 3.24 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.26 ​ ​ 0.27 ​ 0 ​ August 29, 2022 ​ 113 ​ ​ 3.24 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.26 ​ ​ 0.27 ​ 0 ​ August 31, 2022 ​ 113 ​ ​ 3.28 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.25 ​ 0 ​ September 21, 2022 ​ 113 ​ ​ 3.70 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.23 ​ 0 ​ September 23, 2022 ​ 113 ​ ​ 3.91 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Grant Date Volatility ​ Risk-Free Interest Rate ​ Expected Life (In Years) ​ Dividend Yield ​ ​ ​ Common Share Price ​ ​ Strike Price Forfeiture Rate ​ September 23, 2022 ​ 113 ​ ​ 3.91 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ September 26, 2022 ​ 113 ​ ​ 4.11 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.22 ​ ​ 0.22 ​ 0 ​ September 26, 2022 ​ 113 ​ ​ 4.11 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.22 ​ ​ 0.22 ​ 0 ​ October 4, 2022 ​ 112 ​ ​ 3.96 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.22 ​ 0 ​ November 3, 2022 ​ 112 ​ ​ 4.31 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.23 ​ 0 ​ November 7, 2022 ​ 112 ​ ​ 4.35 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.24 ​ 0 ​ November 8, 2022 ​ 112 ​ ​ 4.27 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.24 ​ ​ 0.24 ​ 0 ​ November 9, 2022 ​ 112 ​ ​ 4.24 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.23 ​ ​ 0.23 ​ 0 ​ November 14, 2022 ​ 111 ​ ​ 3.98 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.25 ​ ​ 0.24 ​ 0 ​ November 21, 2022 ​ 111 ​ ​ 3.96 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.21 ​ ​ 0.21 ​ 0 ​ December 1, 2022 ​ 111 ​ ​ 3.65 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.20 ​ ​ 0.21 ​ 0 ​ December 9, 2022 ​ 111 ​ ​ 3.72 ​ ​ 6.25 ​ ​ 0 ​ ​ ​ 0.19 ​ ​ 0.19 ​ 0 ​ ​

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2022
Warrants
Schedule of Warrants Outstanding	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Average ​ ​ Exercise ​ Warrants ​ Remaining Original Issue date ​ Price ​ Outstanding ​ Life February 14, 2020 (Series A) ​ 0.1500 ​ 197,917 ​ 2.12 April 9, 2020 (Series B) ​ 0.1500 ​ 363,501 ​ 2.27 May 29, 2020 (Series C) ​ 0.1500 ​ - ​ - July 7, 2020 (Series D) ​ 0.1600 ​ - ​ - July 1, 2022 (Revo Squared) ​ 0.2201 ​ 10,000,000 ​ 9.51 July 15, 2022 (Assisi) ​ 0.2520 ​ 22,000,000 ​ 9.55 Balance at December 31, 2022 32,561,418 ​
Schedule of Cumulative Warrant Exercises	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants ​ Warrants ​ Warrant Series ​ Exercised ​ ​ Amount ​ Expired ​ ​ Amount ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Series A 21,677,084 ​ $ 4,293 — ​ $ — Series B 17,969,833 ​ 2,695 — ​ — Series C 133,213,333 ​ 19,982 120,000 ​ 18 Series D 187,269,000 ​ 29,963 231,000 ​ 37 Total 360,129,250 ​ $ 56,933 351,000 ​ $ 55

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes
Schedule of Deferred Tax Assets and Liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 ​ 2021 Loss before income taxes ​ $ (19,381) ​ $ (20,717) Expected income tax expense (benefit) ​ (4,458) ​ ​ (4,765) Difference in foreign tax rates ​ 235 ​ ​ 180 Tax rate changes and other adjustments ​ (5) ​ ​ 49 Changes in stock based compensation ​ (1,177) ​ ​ — Foreign accrual property income ​ 9 ​ ​ 16 Stock based compensation and nondeductible expenses ​ 241 ​ ​ 1,394 Prior period adjustment ​ — ​ ​ 162 Share issuance costs recorded in equity ​ — ​ ​ (3,285) Section 382 derecognition ​ — ​ ​ 4,344 Change in valuation allowance ​ 2,789 ​ ​ (428) Total deferred income tax benefit ​ $ (2,366) ​ $ (2,333) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 Deferred tax assets ​ ​ ​ ​ ​ ​ Intangible assets - licenses ​ $ 4,236 ​ $ 4,236 Share issuance costs ​ 2,482 ​ 3,425 Reserves ​ 478 ​ 181 Non-capital loss carried forward - Canada ​ 10,668 ​ 8,387 Net operating losses carried forward - US ​ 2,885 ​ 2,592 Investment tax credits ​ 208 ​ 30 Operating leases ​ 2 ​ 4 Stock-based compensation ​ 3,067 ​ — Other ​ 478 ​ — Total deferred tax assets ​ $ 24,504 ​ $ 18,855 ​ ​ ​ ​ ​ ​ ​ Deferred tax liabilities ​ ​ Property and equipment ​ (491) ​ (139) Intangibles ​ (6,271) ​ (6,079) Other ​ — ​ (148) Total deferred tax liabilities ​ $ (6,762) ​ $ (6,366) ​ ​ ​ ​ ​ ​ ​ Valuation allowance ​ 18,987 ​ 16,198 Net deferred tax liability ​ $ (1,245) ​ $ (3,709) ​
Schedule of Effective Income Tax Rate Reconciliation	​ ​ ​ ​ ​ ​ ​ 2036 $ 3,763 ​ 2037 ​ ​ 4,279 ​ 2038 ​ ​ 5,417 ​ 2039 ​ ​ 6,774 ​ 2040 ​ ​ 7,418 ​ 2041 ​ ​ 9,629 ​ 2042 ​ ​ 9,104 Total ​ $ 46,384 ​ ​ ​ ​ ​ ​ ​ ​ 2035 $ 856 ​ 2036 ​ ​ 1,485 ​ 2037 ​ ​ 3,832 ​ Indefinitely (subject to 80% limitation) ​ ​ 26,283 ​ Derecognized under Section 382 ​ ​ (21,013) Total ​ ​ $ 11,443 ​

Segmented Information (Tables)

Segmented Information (Tables)	12 Months Ended
	Dec. 31, 2022
Segmented Information
Schedule of segments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diagnostics Therapeutics Consolidated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenue ​ $ 391 ​ $ 18,539 ​ $ 18,930 Cost of revenue ​ 265 ​ 5,013 ​ 5,278 Gross profit ​ $ 126 ​ $ 13,526 ​ $ 13,652

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Loss Per Share
Schedule of Earnings Per Share, Basic and Diluted	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Significant Accounting Polici_4

Significant Accounting Policies - PPE (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Undepreciated instruments in property and equipment		$ 8,086	$ 2,014
Leasehold improvements
Undepreciated instruments in property and equipment		$ 1,239	287
Office Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years
Furniture And Equipment [Member]
Undepreciated instruments in property and equipment		$ 111	110
Furniture And Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years
Furniture And Equipment [Member] | Maximum
Property, Plant and Equipment, Useful Life (Year)		7 years
Laboratory Equipment [Member]
Undepreciated instruments in property and equipment		$ 249	$ 225
Laboratory Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years
Laboratory Equipment [Member] | Maximum
Property, Plant and Equipment, Useful Life (Year)		7 years
Machinery And Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years
Machinery And Equipment [Member] | Maximum
Property, Plant and Equipment, Useful Life (Year)		10 years
Truforma [Member]
Capitalization of Inventory	$ 3,364
Undepreciated instruments in property and equipment		$ 3,487
Property, Plant and Equipment, Useful Life (Year)	10 years

Significant Accounting Polici_5

Significant Accounting Policies - Intangibles (Details)	12 Months Ended
	Dec. 31, 2022
Computer Software and Website, Intangible Asset [Member]
Intangible assets indefinite useful lives (Year)	3 years
Customer relationships | Minimum
Intangible assets indefinite useful lives (Year)	11 years
Customer relationships | Maximum
Intangible assets indefinite useful lives (Year)	19 years
Developed Technology Rights | Minimum
Intangible assets indefinite useful lives (Year)	10 years
Developed Technology Rights | Maximum
Intangible assets indefinite useful lives (Year)	15 years
E-commerce technology
Intangible assets indefinite useful lives (Year)	2 years
Trademarks
Intangible assets indefinite useful lives (Year)	15 years
Tradename | Minimum
Intangible assets indefinite useful lives (Year)	5 years
Tradename | Maximum
Intangible assets indefinite useful lives (Year)	19 years

Significant Accounting Polici_6

Significant Accounting Policies (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($)
Net revenue	$ 18,930	$ 4,133
Construction in progress	$ 692	420
Payment term	30 days
Allowance for credit loss on accounts receivable	$ 71
Number of reportable segments | segment	2
Diagnostics
Net revenue	$ 391	125
Diagnostics | Consumables
Net revenue	391	125
Therapeutics
Net revenue	18,539	4,008
Therapeutics | Consumables
Net revenue	2,072
Therapeutics | Instruments
Net revenue	7,269	1,793
Therapeutics | Trodes
Net revenue	8,681	2,073
Therapeutics | Other revenue
Net revenue	$ 517	$ 142

Investment Securities (Details)

Investment Securities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Investment securities
Acquisition Cost	$ 147,797
Accretion / (Amortization)	847
Unrealized Gain / (Loss)	(1,061)
Estimated Fair Value	147,583
Accrued interest receivable	677
Commercial paper
Investment securities
Acquisition Cost	30,634
Accretion / (Amortization)	471
Unrealized Gain / (Loss)	(139)
Estimated Fair Value	30,966
Corporate notes / bonds
Investment securities
Acquisition Cost	44,115
Accretion / (Amortization)	192
Unrealized Gain / (Loss)	(547)
Estimated Fair Value	43,760
Debt security
Investment securities
Acquisition Cost	1,000
Estimated Fair Value	1,000
Money market funds
Investment securities
Acquisition Cost	10,196
Estimated Fair Value	10,196
US govt agencies
Investment securities
Acquisition Cost	46,223
Accretion / (Amortization)	85
Unrealized Gain / (Loss)	(230)
Estimated Fair Value	46,078
US treasuries
Investment securities
Acquisition Cost	15,629
Accretion / (Amortization)	99
Unrealized Gain / (Loss)	(145)
Estimated Fair Value	$ 15,583

Investment Securities - Maturit

Investment Securities - Maturities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Investment Securities
Acquisition Cost, Original maturities of 90 days or less	$ 19,127
Acquisition Cost, Original maturities of 91-365 days	87,528
Acquisition Cost, Original maturities of 365+ days	41,142
Acquisition Cost	147,797
Fair Value, Original maturities of 90 days or less	19,178
Fair Value, Original maturities of 91-365 days	87,693
Fair Value, Original maturities of 365+ days	40,712
Estimated Fair Value	$ 147,583

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Debt security $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Fair value
Convertible note receivable	$ 1
Unrealized gain (loss)	0
Impairment of investments	$ 0

Fair Value Measurements - Inves

Fair Value Measurements - Investments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Fair value
Total investment securities	$ 147,583
Commercial paper
Fair value
Total investment securities	30,966
Corporate notes / bonds
Fair value
Total investment securities	43,760
Debt security
Fair value
Total investment securities	1,000
Money market funds
Fair value
Total investment securities	10,196
U.S. govt. agencies
Fair value
Total investment securities	46,078
U.S. treasuries
Fair value
Total investment securities	15,583
Recurring
Fair value
Total investment securities	147,583
Recurring | Commercial paper
Fair value
Total investment securities	30,966
Recurring | Corporate notes / bonds
Fair value
Total investment securities	43,760
Recurring | Debt security
Fair value
Total investment securities	1,000
Recurring | Money market funds
Fair value
Total investment securities	10,196
Recurring | U.S. govt. agencies
Fair value
Total investment securities	46,078
Recurring | U.S. treasuries
Fair value
Total investment securities	15,583
Recurring | Level 1
Fair value
Total investment securities	71,857
Recurring | Level 1 | Money market funds
Fair value
Total investment securities	10,196
Recurring | Level 1 | U.S. govt. agencies
Fair value
Total investment securities	46,078
Recurring | Level 1 | U.S. treasuries
Fair value
Total investment securities	15,583
Recurring | Level 2
Fair value
Total investment securities	74,726
Recurring | Level 2 | Commercial paper
Fair value
Total investment securities	30,966
Recurring | Level 2 | Corporate notes / bonds
Fair value
Total investment securities	43,760
Recurring | Level 3
Fair value
Total investment securities	1,000
Recurring | Level 3 | Debt security
Fair value
Total investment securities	$ 1,000

Fair Value Measurements - Balan

Fair Value Measurements - Balance sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair value, balance sheet
Cash and cash equivalents	$ 27,399	$ 194,952
Available-For-Sale (Current)	87,693
Available-For-Sale (Non-Current)	40,712
Estimated Fair Value	147,583
Commercial paper
Fair value, balance sheet
Estimated Fair Value	30,966
Corporate notes / bonds
Fair value, balance sheet
Estimated Fair Value	43,760
Debt security
Fair value, balance sheet
Estimated Fair Value	1,000
Money market funds
Fair value, balance sheet
Estimated Fair Value	10,196
U.S. govt. agencies
Fair value, balance sheet
Estimated Fair Value	46,078
U.S. treasuries
Fair value, balance sheet
Estimated Fair Value	15,583
Recurring
Fair value, balance sheet
Cash and cash equivalents	19,178
Available-For-Sale (Current)	87,693
Available-For-Sale (Non-Current)	40,712
Estimated Fair Value	147,583
Recurring | Commercial paper
Fair value, balance sheet
Available-For-Sale (Current)	30,966
Estimated Fair Value	30,966
Recurring | Corporate notes / bonds
Fair value, balance sheet
Available-For-Sale (Current)	24,272
Available-For-Sale (Non-Current)	19,488
Estimated Fair Value	43,760
Recurring | Debt security
Fair value, balance sheet
Available-For-Sale (Non-Current)	1,000
Estimated Fair Value	1,000
Recurring | Money market funds
Fair value, balance sheet
Cash and cash equivalents	10,196
Estimated Fair Value	10,196
Recurring | U.S. govt. agencies
Fair value, balance sheet
Cash and cash equivalents	8,982
Available-For-Sale (Current)	23,597
Available-For-Sale (Non-Current)	13,499
Estimated Fair Value	46,078
Recurring | U.S. treasuries
Fair value, balance sheet
Available-For-Sale (Current)	8,858
Available-For-Sale (Non-Current)	6,725
Estimated Fair Value	$ 15,583

Business Combinations - 2022 (D

Business Combinations - 2022 (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 15, 2022	Jul. 01, 2022	Dec. 31, 2022
Assisi
Business acquisition
Purchase price	$ 18,293
Escrow deposit	$ 1,400
Warrant term	10 years
Warrant to purchase common stock	22,000,000
Warrant, exercise price (in dollars per share)	$ 0.252
Assisi | One year anniversary
Business acquisition
Decrease escrow	$ (500)
Assisi | 18-month anniversary
Business acquisition
Escrow deposit	$ 900
Escrow deposit term	18 months
Revo Squared
Business acquisition
Purchase price		$ 6,011
Warrant term		10 years
Warrant to purchase common stock		10,000,000
Warrant, exercise price (in dollars per share)		$ 0.2201
Contingent consideration milestones		$ 4,000
Contingent consideration fair value		2,000	$ 1,500
Goodwill expected to be deductible		6,528
Revo Squared | Indemnification obligation
Business acquisition
Escrow deposit		$ 500
Escrow deposit term		15 months
Revo Squared | Earnout payment at $5 million
Business acquisition
Contingent consideration milestones		$ 2,000
Earnout milestone basis		5,000
Revo Squared | Earnout payment at $10 million
Business acquisition
Contingent consideration milestones		2,000
Earnout milestone basis		$ 10,000

Business Combinations - 2022 pu

Business Combinations - 2022 purchase allocation (Details) - USD ($) $ in Thousands			12 Months Ended
	Jul. 15, 2022	Jul. 01, 2022	Dec. 31, 2022	Dec. 31, 2021
Business acquisition
Goodwill			$ 63,979	$ 43,288
Electronic Commerce / Website
Business acquisition
Intangible assets indefinite useful lives			2 years
Assisi
Business acquisition
Inventory	$ 220
Prepaid expenses and deposits	271
Other receivables	200
Right of use asset	260
Total assets acquired	8,751
Current portion of lease obligations	49
Non current portion of lease obligations	211
Other non current liabilities	45
Total liabilities assumed	305
Net assets acquired, excluding goodwill	8,446
Goodwill	14,535
Net assets acquired	22,981
Assisi | Electronic Commerce / Website
Business acquisition
Intangible Assets	$ 200
Intangible assets indefinite useful lives	2 years
Assisi | Tradename
Business acquisition
Intangible Assets	$ 300
Intangible assets indefinite useful lives	5 years
Assisi | Developed technology
Business acquisition
Intangible Assets	$ 4,500
Intangible assets indefinite useful lives	10 years
Assisi | Customer relationships
Business acquisition
Intangible Assets	$ 2,800
Intangible assets indefinite useful lives	19 years
Assisi | Initial allocation of consideration
Business acquisition
Inventory	$ 220
Prepaid expenses and deposits	271
Other receivables	406
Total assets acquired	8,697
Other non current liabilities	45
Total liabilities assumed	45
Net assets acquired, excluding goodwill	8,652
Goodwill	14,329
Net assets acquired	22,981
Assisi | Initial allocation of consideration | Electronic Commerce / Website
Business acquisition
Intangible Assets	200
Assisi | Initial allocation of consideration | Tradename
Business acquisition
Intangible Assets	300
Assisi | Initial allocation of consideration | Developed technology
Business acquisition
Intangible Assets	4,500
Assisi | Initial allocation of consideration | Customer relationships
Business acquisition
Intangible Assets	2,800
Assisi | Measurement period adjustment
Business acquisition
Other receivables	(206)
Right of use asset	260
Total assets acquired	54
Current portion of lease obligations	49
Non current portion of lease obligations	211
Total liabilities assumed	260
Net assets acquired, excluding goodwill	(206)
Goodwill	$ 206
Revo Squared
Business acquisition
Cash and cash equivalents		$ 8
Inventory		10
Total assets acquired		3,718
Earnout liabilities		2,000
Total liabilities assumed		2,000
Net assets acquired, excluding goodwill		1,718
Goodwill		6,070
Net assets acquired		7,788
Revo Squared | Tradename
Business acquisition
Intangible Assets		$ 200
Intangible assets indefinite useful lives		5 years
Revo Squared | Developed technology
Business acquisition
Intangible Assets		$ 2,300
Intangible assets indefinite useful lives		10 years
Revo Squared | Customer relationships
Business acquisition
Intangible Assets		$ 1,200
Intangible assets indefinite useful lives		16 years
Revo Squared | Initial allocation of consideration
Business acquisition
Cash and cash equivalents		$ 8
Inventory		10
Total assets acquired		3,718
Earnout liabilities		2,458
Total liabilities assumed		2,458
Net assets acquired, excluding goodwill		1,260
Goodwill		6,528
Net assets acquired		7,788
Revo Squared | Initial allocation of consideration | Tradename
Business acquisition
Intangible Assets		200
Revo Squared | Initial allocation of consideration | Developed technology
Business acquisition
Intangible Assets		2,300
Revo Squared | Initial allocation of consideration | Customer relationships
Business acquisition
Intangible Assets		1,200
Revo Squared | Measurement period adjustment
Business acquisition
Earnout liabilities		(458)
Total liabilities assumed		(458)
Net assets acquired, excluding goodwill		458
Goodwill		$ (458)

Business Combinations - Purchas

Business Combinations - Purchase consideration (Details) - USD ($) $ in Thousands			12 Months Ended
	Jul. 15, 2022	Jul. 01, 2022	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Cash payment for acquisition			$ 24,304	$ 71,399
Assisi
Business Acquisition [Line Items]
Cash payment for acquisition	$ 18,293
Fair value of warrants	4,688
Total	$ 22,981
Revo Squared
Business Acquisition [Line Items]
Cash payment for acquisition		$ 6,011
Fair value of warrants		1,777
Total		$ 7,788

Business Combinations - Proform

Business Combinations - Proforma (Details) - Assisi - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
Net revenue-proforma	$ 21,838	$ 8,841
Net losses-proforma	$ (18,038)	$ (18,822)
Assisi
Net revenue-proforma			$ 2,908	$ 4,708
Net losses-proforma			$ (639)	$ (438)

Business Combinations - PulseVe

Business Combinations - PulseVet (Details) - PulseVet $ in Thousands	Oct. 01, 2021 USD ($)
Business acquisition
Ownership interest (as a percent)	100%
Cash payment for acquisition	$ 71,929
Goodwill expected to be deductible	$ 44,915

Business Combinations - Pulse_2

Business Combinations - PulseVet purchase price allocation (Details) - USD ($) $ in Thousands	Oct. 01, 2021	Dec. 31, 2022	Dec. 31, 2021
Business acquisition
Goodwill		$ 63,979	$ 43,288
PulseVet
Business acquisition
Cash and cash equivalents	$ 529
Trade receivables	269
Inventory	871
Prepaid expenses and deposits	365
Other receivables	150
Property and equipment	125
Other Assets	334
Total assets acquired	36,293
Accounts payable and accrued liabilities	569
Income tax payable	44
Deferred revenue	61
Liability for contracts with customers	332
Deferred tax liabilities	6,324
Other non current liabilities	408
Total liabilities assumed	7,738
Net assets acquired, excluding goodwill	28,555
Goodwill	43,374
Net assets acquired	71,929
PulseVet | Customer relationships
Business acquisition
Intangible Assets	$ 22,650
Intangible assets indefinite useful lives	11 years
PulseVet | Technology
Business acquisition
Intangible Assets	$ 8,650
Intangible assets indefinite useful lives	15 years
PulseVet | Tradename
Business acquisition
Intangible Assets	$ 2,350
Intangible assets indefinite useful lives	19 years
PulseVet | Previously Reported [Member]
Business acquisition
Cash and cash equivalents	$ 526
Trade receivables	269
Inventory	840
Prepaid expenses and deposits	365
Property and equipment	125
Other Assets	69
Total assets acquired	35,844
Accounts payable and accrued liabilities	1,112
Income tax payable	44
Deferred revenue	61
Liability for contracts with customers	332
Deferred tax liabilities	7,138
Other non current liabilities	143
Total liabilities assumed	8,830
Net assets acquired, excluding goodwill	27,014
Goodwill	44,915
Net assets acquired	71,929
PulseVet | Previously Reported [Member] | Customer relationships
Business acquisition
Intangible Assets	22,650
PulseVet | Previously Reported [Member] | Technology
Business acquisition
Intangible Assets	8,650
PulseVet | Previously Reported [Member] | Tradename
Business acquisition
Intangible Assets	2,350
PulseVet | Revision of Prior Period, Adjustment [Member]
Business acquisition
Cash and cash equivalents	3
Inventory	31
Other receivables	150
Other Assets	265
Total assets acquired	449
Accounts payable and accrued liabilities	(543)
Deferred tax liabilities	(814)
Other non current liabilities	265
Total liabilities assumed	(1,092)
Net assets acquired, excluding goodwill	1,541
Goodwill	$ (1,541)

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Raw Materials	$ 1,685	$ 890
Finished Goods	182	140
Purchased Inventory	919	1,848
Total	2,786	2,878
Reserves	(40)	(30)
Net inventory	2,746	2,848
Diagnostics
Purchased Inventory	919	1,848
Total	919	1,848
Reserves	(18)	(9)
Net inventory	901	1,839
Therapeutics
Raw Materials	1,685	890
Finished Goods	182	140
Total	1,867	1,030
Reserves	(22)	(21)
Net inventory	$ 1,845	$ 1,009

Prepaid Expenses and Deposits_2

Prepaid Expenses and Deposits (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expenses and Deposits.
Deposits	$ 1,886	$ 1,340
Prepaid marketing	114	83
Prepaid insurance	614	599
Prepaid taxes	753
Other	620	214
Total prepaid expenses and deposits	$ 3,987	$ 2,236

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Undepreciated instruments in property and equipment	$ 8,086	$ 2,014
Accumulated depreciation and amortization	1,277	884
Net property and equipment	6,809	1,130
Depreciation expense	426	265
Machinery and office equipment
Undepreciated instruments in property and equipment	6,487	1,392
Furniture and equipment
Undepreciated instruments in property and equipment	111	110
Laboratory equipment
Undepreciated instruments in property and equipment	249	225
Leasehold improvements
Undepreciated instruments in property and equipment	$ 1,239	$ 287

Intangible Assets - Summary (De

Intangible Assets - Summary (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets
Intangible assets	$ 46,479	$ 34,240
Accumulated amortization	4,680	1,064
Total	41,799	33,176
Computer software
Intangible Assets
Intangible assets	350	28
Customer relationships
Intangible Assets
Intangible assets	26,651	22,650
Technology
Intangible Assets
Intangible assets	15,650	8,650
Trademarks
Intangible Assets
Intangible assets	16	16
Tradename
Intangible Assets
Intangible assets	2,850	2,350
Electronic Commerce / Website
Intangible Assets
Intangible assets	$ 962	$ 546

Intangible Assets - Amortizatio

Intangible Assets - Amortization (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets
2023	$ 4,098
2024	4,067
2025	3,903
2026	3,781
2027 and beyond	25,950
Total	41,799	$ 33,176
Amortization - intangible assets	$ 3,616	$ 874

Leases (Details)

Leases (Details) $ in Thousands						3 Months Ended	12 Months Ended
	Jul. 15, 2022 USD ($) ft²	Jul. 01, 2022 USD ($) ft²	Apr. 01, 2022 USD ($) ft²	Sep. 15, 2021 USD ($)	Feb. 01, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Right-of-use asset							$ 1,665	$ 1,320
Operating lease expense							661	411
Total							1,738	1,379
Assisi
Area of warehousing space | ft²	5,185
Research and development expenses
Operating lease expense							62	95
General and administrative expenses
Operating lease expense							$ 599	$ 316
Wickfield Phoenix office lease
Operating lease term					48 months
Right-of-use asset					$ 1,258
Discount rate (as a percent)					3.95%
(Gain) loss on right-of-use assets						$ 24
Wickfield Phoenix office lease | Minimum
Monthly rent payment					$ 12
Wickfield Phoenix office lease | Maximum
Monthly rent payment					$ 31
Wickfield Phoenix warehouse lease
Operating lease term				41 months
Right-of-use asset				$ 366
Discount rate (as a percent)				3.95%
Wickfield Phoenix warehouse lease | Minimum
Monthly rent payment				$ 5
Wickfield Phoenix warehouse lease | Maximum
Monthly rent payment				$ 10
ULF Northfield Business Center
Operating lease term			61 months
Right-of-use asset			$ 546
Discount rate (as a percent)			3.95%
Lease area | ft²			12,400
ULF Northfield Business Center | Minimum
Monthly rent payment			$ 9
ULF Northfield Business Center | Maximum
Monthly rent payment			$ 11
Lebow 1031 Legacy
Operating lease term		18 months
Monthly rent payment		$ 4
Right-of-use asset		$ 67
Discount rate (as a percent)		7%
Lease area | ft²		4,626
Wheelership and The Realty Associates Agreement
Right-of-use asset	$ 260
Discount rate (as a percent)	7%
Remaining lease period	52 months
Wheelership and The Realty Associates Agreement | Minimum
Monthly rent payment	$ 4
Wheelership and The Realty Associates Agreement | Maximum
Monthly rent payment	$ 6

Leases - Balance sheet (Details

Leases - Balance sheet (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Aggregate lease commitments	$ 2,759	$ 1,779
Less: impact of present value	(262)	(155)
Balance, cost	2,497	1,624
Straight line amortization	946	346
Interest	(114)	(42)
Balance, reduction in right-of-use asset	832	304
Net book value	1,665	1,320
Additions	2,520	1,647
Payments	(896)	(310)
Interest	114	42
Current portion of lease liabilities	641	415
Long term portion of lease liabilities	1,097	964
Total lease liabilities	$ 1,738	$ 1,379

Leases - Undiscounted liability

Leases - Undiscounted liability (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Leases
2023	$ 706
2024	679
2025	237
2026	197
2027	44
Total lease payments	1,863
Less imputed interest	125
Total	$ 1,738	$ 1,379

Leases - Weighted-average remai

Leases - Weighted-average remaining lease term and discount rate (Details)	Dec. 31, 2022
Leases
Weighted-average remaining lease term	2 years 10 months 24 days
Weighted-average discount rate	4.50%

Common Stock - Narrative (Detai

Common Stock - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Feb. 08, 2021	Dec. 31, 2021
Cash proceeds from issuance of common shares and warrants	$ 199,525	$ 199,525
Stock issuance costs	$ 14,281	$ 14,281
The Common Shares Offering [Member]
Shares Issued, Price Per Share (in dollars per share)	$ 1.90
Stock Issued During Period, Shares, New Issues (in shares)	91,315,790
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	13,697,368

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock-Based Compensation
Stock options granted (in shares)	47,292,219	35,471,000
Stock issuance from exercise of stock options (in shares)		7,022,776
Vesting period	4 years	4 years
Expiration period	10 years	5 years
Reclassification of additional paid-in-capital to common stock		$ 1,051
Cash received from stock option exercises		1,769,000
Sharebased Payment Arrangement Expense	$ 7,891,000	$ 7,092,000

Stock-Based Compensation - Opti

Stock-Based Compensation - Option activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock-Based Compensation
Options Outstanding, beginning balance (in shares)	50,717,724
Stock options granted (in shares)	47,292,219	35,471,000
Stock options forfeited (in shares)	4,300,000
Vested stock options expired (in shares)	9,597,500
Options Outstanding, ending balance (in shares)	84,112,443	50,717,724
Vested (in shares)	23,850,099
Weighted Avg Exercise Price Options Outstanding (in dollars per share)	$ 0.4466
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	0.2692
Weighted Avg Exercise Price Stock options forfeited (in dollars per share)	0.6108
Weighted Avg Exercise Price Vested Stock options expired (in dollars per share)	0.2601
Weighted Avg Exercise Price Options Outstanding (in dollars per share)	0.3602	$ 0.4466
Weighted Avg Exercise Price Vested (in dollars per share)	$ 0.3698

Stock-Based Compensation - Op_2

Stock-Based Compensation - Option details (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.2692
Number of Options Issued and Outstanding (in shares)	84,112,443	50,717,724
Number of Vested Options Outstanding (in shares)	23,850,099
Number of Unvested Options Outstanding (in shares)	60,262,344
March 14, 2020
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.19
Number of Options Issued and Outstanding (in shares)	1,133,557
Number of Vested Options Outstanding (in shares)	837,182
Number of Unvested Options Outstanding (in shares)	296,375
Weighted Avg Remaining Life Outstanding	2 years 2 months 12 days
July 9, 2020
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.18
Number of Options Issued and Outstanding (in shares)	175,000
Number of Vested Options Outstanding (in shares)	131,250
Number of Unvested Options Outstanding (in shares)	43,750
Weighted Avg Remaining Life Outstanding	2 years 6 months 7 days
August 25, 2020
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.13
Number of Options Issued and Outstanding (in shares)	20,000
Number of Vested Options Outstanding (in shares)	10,000
Number of Unvested Options Outstanding (in shares)	10,000
Weighted Avg Remaining Life Outstanding	2 years 7 months 24 days
October 1, 2020
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.11
Number of Options Issued and Outstanding (in shares)	266,667
Number of Vested Options Outstanding (in shares)	191,667
Number of Unvested Options Outstanding (in shares)	75,000
Weighted Avg Remaining Life Outstanding	2 years 9 months
October 20, 2020
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.09
Number of Options Issued and Outstanding (in shares)	20,000
Number of Vested Options Outstanding (in shares)	15,000
Number of Unvested Options Outstanding (in shares)	5,000
Weighted Avg Remaining Life Outstanding	2 years 9 months 21 days
December 31, 2020
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.23
Number of Options Issued and Outstanding (in shares)	15,742,500
Number of Vested Options Outstanding (in shares)	13,002,500
Number of Unvested Options Outstanding (in shares)	2,740,000
Weighted Avg Remaining Life Outstanding	3 years
February 26, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 1.87
Number of Options Issued and Outstanding (in shares)	100,000
Number of Vested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	3 years 1 month 28 days
March 1, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 2.06
Number of Options Issued and Outstanding (in shares)	200,000
Number of Vested Options Outstanding (in shares)	100,000
Number of Unvested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	3 years 2 months 1 day
March 8, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 1.88
Number of Options Issued and Outstanding (in shares)	100,000
Number of Vested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	3 years 2 months 8 days
March 15, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 2.49
Number of Options Issued and Outstanding (in shares)	100,000
Number of Vested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	3 years 2 months 15 days
May 12, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.78
Number of Options Issued and Outstanding (in shares)	3,400,000
Number of Vested Options Outstanding (in shares)	1,700,000
Number of Unvested Options Outstanding (in shares)	1,700,000
Weighted Avg Remaining Life Outstanding	3 years 4 months 9 days
May 14, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.75
Number of Options Issued and Outstanding (in shares)	3,200,000
Number of Vested Options Outstanding (in shares)	850,000
Number of Unvested Options Outstanding (in shares)	2,350,000
Weighted Avg Remaining Life Outstanding	3 years 4 months 13 days
August 11, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.57
Number of Options Issued and Outstanding (in shares)	525,000
Number of Vested Options Outstanding (in shares)	225,000
Number of Unvested Options Outstanding (in shares)	300,000
Weighted Avg Remaining Life Outstanding	3 years 7 months 9 days
August 18, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.50
Number of Options Issued and Outstanding (in shares)	200,000
Number of Vested Options Outstanding (in shares)	50,000
Number of Unvested Options Outstanding (in shares)	150,000
Weighted Avg Remaining Life Outstanding	3 years 7 months 17 days
August 23, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.50
Number of Options Issued and Outstanding (in shares)	25,000
Number of Vested Options Outstanding (in shares)	25,000
Weighted Avg Remaining Life Outstanding	3 years 7 months 24 days
September 13, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.57
Number of Options Issued and Outstanding (in shares)	800,000
Number of Vested Options Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	600,000
Weighted Avg Remaining Life Outstanding	3 years 8 months 12 days
October 01, 2021
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.58
Number of Options Issued and Outstanding (in shares)	12,412,500
Number of Vested Options Outstanding (in shares)	3,112,500
Number of Unvested Options Outstanding (in shares)	9,300,000
Weighted Avg Remaining Life Outstanding	3 years 9 months
January 3, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.36
Number of Options Issued and Outstanding (in shares)	100,000
Number of Unvested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	4 years 3 days
January 4, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.35
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 3 days
January 14, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.35
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 14 days
January 16, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.35
Number of Options Issued and Outstanding (in shares)	50,000
Number of Unvested Options Outstanding (in shares)	50,000
Weighted Avg Remaining Life Outstanding	4 years 18 days
January 18, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.35
Number of Options Issued and Outstanding (in shares)	100,000
Number of Unvested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	4 years 18 days
February 14, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.30
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 1 month 17 days
February 21, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.37
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 1 month 24 days
February 25, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.35
Number of Options Issued and Outstanding (in shares)	12,100,000
Number of Unvested Options Outstanding (in shares)	12,100,000
Weighted Avg Remaining Life Outstanding	4 years 1 month 28 days
March 30, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.35
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 3 months
April 1, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.34
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 3 months
April 6, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.32
Number of Options Issued and Outstanding (in shares)	100,000
Number of Unvested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	4 years 3 months 7 days
April 11, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.31
Number of Options Issued and Outstanding (in shares)	75,000
Number of Unvested Options Outstanding (in shares)	75,000
Weighted Avg Remaining Life Outstanding	4 years 3 months 10 days
May 2, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.25
Number of Options Issued and Outstanding (in shares)	300,000
Number of Unvested Options Outstanding (in shares)	300,000
Weighted Avg Remaining Life Outstanding	4 years 4 months 2 days
May 9, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.21
Number of Options Issued and Outstanding (in shares)	700,000
Number of Unvested Options Outstanding (in shares)	700,000
Weighted Avg Remaining Life Outstanding	4 years 4 months 9 days
May 11, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.20
Number of Options Issued and Outstanding (in shares)	400,000
Number of Unvested Options Outstanding (in shares)	400,000
Weighted Avg Remaining Life Outstanding	4 years 4 months 9 days
May 16, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.23
Number of Options Issued and Outstanding (in shares)	100,000
Number of Unvested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	4 years 4 months 17 days
May 31, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.24
Number of Options Issued and Outstanding (in shares)	500,000
Number of Unvested Options Outstanding (in shares)	500,000
Weighted Avg Remaining Life Outstanding	4 years 5 months 1 day
June 1, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.25
Number of Options Issued and Outstanding (in shares)	500,000
Number of Unvested Options Outstanding (in shares)	500,000
Weighted Avg Remaining Life Outstanding	4 years 5 months 1 day
June 6, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.26
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 5 months 4 days
June 13, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.24
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 5 months 12 days
June 17, 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.24
Number of Options Issued and Outstanding (in shares)	3,100,000
Number of Vested Options Outstanding (in shares)	3,100,000
Weighted Avg Remaining Life Outstanding	4 years 5 months 15 days
July 1 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.21
Number of Options Issued and Outstanding (in shares)	350,000
Number of Unvested Options Outstanding (in shares)	350,000
Weighted Avg Remaining Life Outstanding	4 years 6 months
July 5 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.22
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 6 months 3 days
July 6 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.26
Number of Options Issued and Outstanding (in shares)	100,000
Number of Unvested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	4 years 6 months 7 days
July 25 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.25
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 6 months 25 days
August 1 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.28
Number of Options Issued and Outstanding (in shares)	100,000
Number of Unvested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	4 years 7 months 2 days
August 5 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.34
Number of Options Issued and Outstanding (in shares)	2,850,000
Number of Unvested Options Outstanding (in shares)	2,850,000
Weighted Avg Remaining Life Outstanding	4 years 7 months 6 days
August 8 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.39
Number of Options Issued and Outstanding (in shares)	100,000
Number of Unvested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	4 years 7 months 9 days
August 17 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.31
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 7 months 17 days
August 19 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.27
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 7 months 20 days
August 22 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.27
Number of Options Issued and Outstanding (in shares)	400,000
Number of Unvested Options Outstanding (in shares)	400,000
Weighted Avg Remaining Life Outstanding	4 years 7 months 20 days
August 29 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.27
Number of Options Issued and Outstanding (in shares)	400,000
Number of Unvested Options Outstanding (in shares)	400,000
Weighted Avg Remaining Life Outstanding	4 years 7 months 28 days
August 31 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.25
Number of Options Issued and Outstanding (in shares)	800,000
Number of Unvested Options Outstanding (in shares)	800,000
Weighted Avg Remaining Life Outstanding	4 years 8 months 1 day
September 21 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.23
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 8 months 23 days
September 23 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.21
Number of Options Issued and Outstanding (in shares)	400,000
Number of Unvested Options Outstanding (in shares)	400,000
Weighted Avg Remaining Life Outstanding	4 years 8 months 23 days
September 26 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.22
Number of Options Issued and Outstanding (in shares)	300,000
Number of Unvested Options Outstanding (in shares)	300,000
Weighted Avg Remaining Life Outstanding	4 years 8 months 26 days
October 4 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.22
Number of Options Issued and Outstanding (in shares)	4,000,000
Number of Unvested Options Outstanding (in shares)	4,000,000
Weighted Avg Remaining Life Outstanding	4 years 9 months 3 days
November 3 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.23
Number of Options Issued and Outstanding (in shares)	200,000
Number of Unvested Options Outstanding (in shares)	200,000
Weighted Avg Remaining Life Outstanding	4 years 10 months 2 days
November 7 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.24
Number of Options Issued and Outstanding (in shares)	500,000
Number of Unvested Options Outstanding (in shares)	500,000
Weighted Avg Remaining Life Outstanding	4 years 10 months 6 days
November 8 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.24
Number of Options Issued and Outstanding (in shares)	4,950,000
Number of Unvested Options Outstanding (in shares)	4,950,000
Weighted Avg Remaining Life Outstanding	4 years 10 months 9 days
November 9 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.23
Number of Options Issued and Outstanding (in shares)	300,000
Number of Unvested Options Outstanding (in shares)	300,000
Weighted Avg Remaining Life Outstanding	4 years 10 months 9 days
November 14 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.24
Number of Options Issued and Outstanding (in shares)	350,000
Number of Unvested Options Outstanding (in shares)	350,000
Weighted Avg Remaining Life Outstanding	4 years 10 months 13 days
November 21 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.21
Number of Options Issued and Outstanding (in shares)	50,000
Number of Unvested Options Outstanding (in shares)	50,000
Weighted Avg Remaining Life Outstanding	4 years 10 months 20 days
December 1 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.21
Number of Options Issued and Outstanding (in shares)	100,000
Number of Unvested Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life Outstanding	4 years 11 months 1 day
December 9 2022
Stock-Based Compensation
Exercise Price (in dollars per share)	$ 0.19
Number of Options Issued and Outstanding (in shares)	8,717,219
Number of Unvested Options Outstanding (in shares)	8,717,219
Weighted Avg Remaining Life Outstanding	4 years 11 months 8 days

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions (Details) - USD ($) $ / shares in Units, $ in Thousands																																																										12 Months Ended
	Dec. 09, 2022	Dec. 01, 2022	Nov. 21, 2022	Nov. 14, 2022	Nov. 09, 2022	Nov. 08, 2022	Nov. 07, 2022	Nov. 03, 2022	Oct. 04, 2022	Sep. 26, 2022	Sep. 23, 2022	Sep. 21, 2022	Aug. 31, 2022	Aug. 29, 2022	Aug. 22, 2022	Aug. 19, 2022	Aug. 17, 2022	Aug. 11, 2022	Aug. 08, 2022	Aug. 05, 2022	Aug. 01, 2022	Jul. 25, 2022	Jul. 06, 2022	Jul. 05, 2022	Jul. 01, 2022	Jun. 17, 2022	Jun. 13, 2022	Jun. 06, 2022	Jun. 01, 2022	May 31, 2022	May 16, 2022	May 12, 2022	May 11, 2022	May 09, 2022	May 02, 2022	Apr. 11, 2022	Apr. 06, 2022	Apr. 01, 2022	Mar. 30, 2022	Feb. 25, 2022	Feb. 21, 2022	Feb. 14, 2022	Jan. 18, 2022	Jan. 16, 2022	Jan. 14, 2022	Jan. 04, 2022	Jan. 03, 2022	Oct. 01, 2021	Aug. 23, 2021	Aug. 18, 2021	Aug. 11, 2021	May 14, 2021	May 12, 2021	Mar. 15, 2021	Mar. 08, 2021	Mar. 01, 2021	Feb. 26, 2021	Dec. 31, 2022	Dec. 31, 2021
Stock-Based Compensation
Volatility	111%	111%	111%	111%	112%	112%	112%	112%	112%			113%	113%			113%	112%		112%			112%	112%	112%			112%	113%	113%	113%	113%		113%	113%	113%	114%	114%	114%	114%	113%	113%	113%	114%	114%	114%	114%	114%	116%	116%	116%	116%		118%	117%	117%	117%	117%
Risk-free interest rate	3.72%	3.65%	3.96%	3.98%	4.24%	4.27%	4.35%	4.31%	3.96%			3.70%	3.28%			3.09%	3.02%		2.88%			2.94%	2.98%	2.85%			3.55%	3.05%	2.96%	2.84%	2.86%		2.92%	3%	3.03%	2.82%	2.70%	2.53%	2.43%	1.91%	1.89%	1.94%	1.74%	1.73%	1.64%	1.47%	1.50%	1.10%	0.92%	0.93%	0.96%		1.11%	1.06%	1.07%	0.92%	0.95%
Expected life	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months			6 years 3 months	6 years 3 months			6 years 3 months	6 years 3 months		6 years 3 months			6 years 3 months	6 years 3 months	6 years 3 months			6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months		6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months				5 years 9 months	10 years	10 years	10 years
Dividend yield	0%	0%	0%	0%	0%	0%	0%	0%	0%			0%	0%			0%	0%		0%			0%	0%	0%			0%	0%	0%	0%	0%		0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		0%	0%	0%	0%	0%
Common share price (in dollars per share)	$ 0.19	$ 0.20	$ 0.21	$ 0.25	$ 0.23	$ 0.24	$ 0.23	$ 0.23	$ 0.21			$ 0.23	$ 0.24			$ 0.27	$ 0.30		$ 0.38			$ 0.25	$ 0.25	$ 0.22			$ 0.24	$ 0.26	$ 0.25	$ 0.23	$ 0.22		$ 0.20	$ 0.21	$ 0.25	$ 0.30	$ 0.32	$ 0.33	$ 0.35	$ 0.35	$ 0.37	$ 0.29	$ 0.35	$ 0.35	$ 0.35	$ 0.35	$ 0.36	$ 0.57	$ 0.50	$ 0.50	$ 0.56		$ 0.78	$ 2.49	$ 1.88	$ 2.06	$ 1.87
Strike price (in dollars per share)	$ 0.19	$ 0.21	$ 0.21	$ 0.24	$ 0.23	$ 0.24	$ 0.24	$ 0.23	$ 0.22			$ 0.23	$ 0.25			$ 0.27	$ 0.31		$ 0.39			$ 0.25	$ 0.26	$ 0.22			$ 0.24	$ 0.26	$ 0.25	$ 0.24	$ 0.23		$ 0.20	$ 0.21	$ 0.25	$ 0.31	$ 0.32	$ 0.34	$ 0.35	$ 0.35	$ 0.37	$ 0.30	$ 0.35	$ 0.35	$ 0.35	$ 0.35	$ 0.36	$ 0.58	$ 0.50	$ 0.50	$ 0.57		$ 0.78	$ 2.49	$ 1.88	$ 2.06	$ 1.87
Forfeiture rate	0%	0%	0%	0%	0%	0%	0%	0%	0%			0%	0%			0%	0%		0%			0%	0%	0%			0%	0%	0%	0%	0%		0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		0%	0%	0%	0%	0%
Stock-based expense																																																										$ 7,891	$ 7,092
Minimum
Stock-Based Compensation
Expected life																		6 years 2 months 4 days														6 years 2 months 15 days
Maximum
Stock-Based Compensation
Expected life																		6 years 3 months														6 years 2 months 19 days
Grantee One
Stock-Based Compensation
Volatility										113%	113%			113%	113%					112%	112%				112%	112%																										118%
Risk-free interest rate										4.11%	3.91%			3.24%	3.15%					2.94%	2.65%				2.90%	3.02%																										1.06%
Expected life										6 years 3 months	6 years 3 months			6 years 3 months	6 years 3 months					6 years 3 months	6 years 3 months				6 years 3 months	1 year 4 months 13 days																										5 years 9 months
Dividend yield										0%	0%			0%	0%					0%	0%				0%	0%																										0%
Common share price (in dollars per share)										$ 0.22	$ 0.21			$ 0.26	$ 0.27					$ 0.34	$ 0.28				$ 0.21	$ 0.24																										$ 0.76
Strike price (in dollars per share)										$ 0.22	$ 0.21			$ 0.27	$ 0.27					$ 0.34	$ 0.28				$ 0.21	$ 0.24																										$ 0.75
Forfeiture rate										0%	0%			0%	0%					0%	0%				0%	0%																										0%
Grantee Two
Stock-Based Compensation
Volatility										113%	113%			113%	113%					112%	112%				112%	112%																										118%
Risk-free interest rate										4.11%	3.91%			3.24%	3.15%					2.94%	2.65%				2.90%	3.02%																										1.06%
Expected life										6 years 3 months	6 years 3 months			6 years 3 months	6 years 3 months					6 years 3 months	6 years 3 months				6 years 3 months	1 year 7 months 20 days																										6 years 3 months
Dividend yield										0%	0%			0%	0%					0%	0%				0%	0%																										0%
Common share price (in dollars per share)										$ 0.22	$ 0.21			$ 0.26	$ 0.27					$ 0.34	$ 0.28				$ 0.21	$ 0.24																										$ 0.75
Strike price (in dollars per share)										$ 0.22	$ 0.21			$ 0.27	$ 0.27					$ 0.34	$ 0.28				$ 0.21	$ 0.24																										$ 0.75
Forfeiture rate										0%	0%			0%	0%					0%	0%				0%	0%																										0%
Grantee Three
Stock-Based Compensation
Volatility																				112%					112%	112%
Risk-free interest rate																				2.94%					2.90%	3.35%
Expected life																				6 years 3 months					6 years 3 months	4 years 3 months 7 days
Dividend yield																				0%					0%	0%
Common share price (in dollars per share)																				$ 0.34					$ 0.21	$ 0.24
Strike price (in dollars per share)																				$ 0.34					$ 0.21	$ 0.24
Forfeiture rate																				0%					0%	0%
Grantee Four
Stock-Based Compensation
Volatility																				112%
Risk-free interest rate																				2.94%
Expected life																				6 years 3 months
Dividend yield																				0%
Common share price (in dollars per share)																				$ 0.34
Strike price (in dollars per share)																				$ 0.34
Forfeiture rate																				0%

Warrants (Details)

Warrants (Details) - $ / shares			12 Months Ended
	Jul. 15, 2022	Jul. 01, 2022	Dec. 31, 2022
Warrants outstanding (in shares)			32,561,418
Assisi
Warrants outstanding term	10 years
Securities called by warrants (in shares)	22,000,000
Warrant, exercise price (in dollars per share)	$ 0.252
Stock issuance from warrant exercises (in shares)			0
Revo Squared
Warrants outstanding term		10 years
Securities called by warrants (in shares)		10,000,000
Warrant, exercise price (in dollars per share)		$ 0.2201
Stock issuance from warrant exercises (in shares)			0
Series A Warrants
Warrants outstanding (in shares)			197,917
Warrant, exercise price (in dollars per share)			$ 0.1500
Series B Warrants
Warrants outstanding (in shares)			363,501
Warrant, exercise price (in dollars per share)			$ 0.1500
Series C Warrants
Warrant, exercise price (in dollars per share)			0.1500
Series D Warrants
Warrant, exercise price (in dollars per share)			$ 0.1600

Warrants - Outstanding (Details

Warrants - Outstanding (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Warrants and Rights, Outstanding (in shares) | shares	32,561,418
Series A Warrants
Warrants and Rights, Outstanding (in shares) | shares	197,917
Warrant, exercise price (in dollars per share)	$ 0.1500
Warrants, weighted average remaining life (Year)	2 years 1 month 13 days
Series B Warrants
Warrants and Rights, Outstanding (in shares) | shares	363,501
Warrant, exercise price (in dollars per share)	$ 0.1500
Warrants, weighted average remaining life (Year)	2 years 3 months 7 days
Series C Warrants
Warrant, exercise price (in dollars per share)	$ 0.1500
Series D Warrants
Warrant, exercise price (in dollars per share)	$ 0.1600
Revo Squared warrants
Warrants and Rights, Outstanding (in shares) | shares	10,000,000
Warrant, exercise price (in dollars per share)	$ 0.2201
Warrants, weighted average remaining life (Year)	9 years 6 months 3 days
Assisi warrants
Warrants and Rights, Outstanding (in shares) | shares	22,000,000
Warrant, exercise price (in dollars per share)	$ 0.2520
Warrants, weighted average remaining life (Year)	9 years 6 months 18 days

Warrants - Subtotal (Details)

Warrants - Subtotal (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) shares
Sub Total Warrant amount | $	$ 56,933
Warrants Expired | shares	351,000
Warrants Expired, Amount | $	$ 55
Total warrant exercised | shares	360,129,250
Series A Warrants
Sub Total Warrant exercised shares | shares	21,677,084
Sub Total Warrant amount | $	$ 4,293
Series B Warrants
Sub Total Warrant exercised shares | shares	17,969,833
Sub Total Warrant amount | $	$ 2,695
Series C Warrants
Sub Total Warrant exercised shares | shares	133,213,333
Sub Total Warrant amount | $	$ 19,982
Warrants Expired | shares	120,000
Warrants Expired, Amount | $	$ 18
Series D Warrants
Sub Total Warrant exercised shares | shares	187,269,000
Sub Total Warrant amount | $	$ 29,963
Warrants Expired | shares	231,000
Warrants Expired, Amount | $	$ 37

Income Taxes - Rate reconciliat

Income Taxes - Rate reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes
Income tax rate (as a percent)	23%	23%
Loss before income taxes	$ (19,381)	$ (20,717)
Expected income tax expense (benefit)	(4,458)	(4,765)
Difference in foreign rates	235	180
Tax rate changes and other adjustments	(5)	49
Changes in stock based compensation	(1,177)
Stock based compensation and nondeductible expenses	241	1,394
Foreign accrual property income	9	16
Prior period adjustment		162
Share issuance costs recorded in equity		(3,285)
Section 382 derecognition		4,344
Change in valuation allowance	2,789	(428)
Total deferred income tax benefit	$ (2,366)	$ (2,333)

Income Taxes - Deferred (Detail

Income Taxes - Deferred (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets
Intangible assets - licenses	$ 4,236	$ 4,236
Share issuance costs	2,482	3,425
Reserves	478	181
Non-capital loss carried forward - Canada	10,668	8,387
Net operating losses carried forward - US	2,885	2,592
Investment tax credits	208	30
Operating leases	2	4
Stock-based compensation	3,067
Other	478
Total deferred tax assets	24,504	18,855
Deferred tax liabilities
Property and equipment	(491)	(139)
Intangibles	(6,271)	(6,079)
Other		(148)
Total deferred tax liabilities	(6,762)	(6,366)
Valuation allowance	18,987	16,198
Net deferred tax liability	$ (1,245)	$ (3,709)

Income Taxes - Carryforward (De

Income Taxes - Carryforward (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Unrecognized tax benefits		$ 265
Net operating loss carryforwards concluded valuation allowance	$ 1,600
Domestic Tax Authority [Member]
Operating loss carryforwards	46,384
Non-operating loss carryforward		$ 32,456
Domestic Tax Authority [Member] | Tax Year 2036
Operating loss carryforwards	3,763
Domestic Tax Authority [Member] | Tax Year 2037
Operating loss carryforwards	4,279
Domestic Tax Authority [Member] | Tax Year 2038
Operating loss carryforwards	5,417
Domestic Tax Authority [Member] | Tax Year 2039
Operating loss carryforwards	6,774
Domestic Tax Authority [Member] | Tax Year 2040
Operating loss carryforwards	7,418
Domestic Tax Authority [Member] | Tax Year 2041
Operating loss carryforwards	9,629
Domestic Tax Authority [Member] | Tax Year 2042
Operating loss carryforwards	9,104
Foreign Tax Authority [Member]
Operating loss carryforwards	11,443
Foreign Tax Authority [Member] | Tax Year 2035
Operating loss carryforwards	856
Foreign Tax Authority [Member] | Tax Year 2036
Operating loss carryforwards	1,485
Foreign Tax Authority [Member] | Tax Year 2037
Operating loss carryforwards	3,832
Foreign Tax Authority [Member] | Indefinitely (subject to 80% limitation)
Operating loss carryforwards	26,283
Foreign Tax Authority [Member] | Derecognized under Section 382
Operating loss carryforwards	$ 21,013

Commitments and Contingencies (

Commitments and Contingencies (Details) - Seraph Biosciences, Inc. $ in Thousands	May 10, 2018 USD ($)
Future milestone payable in cash	$ 3,500
Future milestone payable in equity	$ 3,500

Segmented Information - Segment

Segmented Information - Segment (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($)
Number of reportable segments | segment	2
Net revenue	$ 18,930	$ 4,133
Cost of revenue	5,278	1,079
Gross profit	13,652	3,054
Diagnostics
Net revenue	391	125
Cost of revenue	265
Gross profit	126
Therapeutics
Net revenue	18,539	$ 4,008
Cost of revenue	5,013
Gross profit	$ 13,526

Loss Per Share (Details)

Loss Per Share (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Loss Per Share
Net loss	$ (17,015)	$ (18,384)
Weighted average shares - basic (in shares)	979,924,052	956,533,761
Denominator for diluted loss per share (in shares)	979,924,052	956,533,761

Loss Per Share - Anti-dilutive

Loss Per Share - Anti-dilutive (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock options
Antidilutive securities
Antidilutive securities (in shares)	84,112,443	50,717,724
Warrants.
Antidilutive securities
Antidilutive securities (in shares)	32,561,418	912,418

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent events	Jan. 13, 2023
Distribution Agreement with Structured Monitoring Products, Inc.
Subsequent events
Distribution agreement term	2 years
Automatic renewals period	12 months
Long-term agreement with Qorvo Biotechnologies, LLC
Subsequent events
Manufacturing transfer process, maximum period	18 months